SIMILAR PATTERN OF AMINO ACIDS MAPPED TO '1N8'


List of Similar Pattern of Amino Acids

Hit pattern: 3D amino acid arrangements similar to known drug binding site
Query pattern: Residues from known binding site for annotated drug that match the hit pattern

(Click on the DrReposER ID to view details on interfaces and similar patterns of amino acids)
(Click on the view link on the last column to view superposed patterns of amino acids)
Filter list by:
DrReposER ID / Desc. Hit
PDBID		 Hit
Macromolecule		 Res.
Matches		 Interface HETATM RMSD Dali
Z-score		 Seq.
Identity (%)		 View Dock
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
1IEP_A_STIA201_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL)		 2og8 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE LCK
(Homo
sapiens) 		10 / 12 LEU A 251
VAL A 259
ALA A 271
GLU A 288
MET A 292
THR A 316
GLY A 322
LEU A 371
ALA A 381
ASP A 382
 None
None
1N8  A 501 ( 3.4A)
1N8  A 501 ( 3.6A)
1N8  A 501 ( 3.6A)
1N8  A 501 ( 3.3A)
1N8  A 501 ( 3.5A)
1N8  A 501 ( 4.3A)
1N8  A 501 ( 3.3A)
1N8  A 501 ( 3.3A)
 0.66A 1iepA-2og8A:
27.0		 1iepA-2og8A:
45.30
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
1IEP_A_STIA201_2
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL)		 2og8 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE LCK
(Homo
sapiens) 		4 / 6 VAL A 301
ILE A 314
MET A 319
ARG A 363
 None
1N8  A 501 ( 4.6A)
1N8  A 501 ( 4.4A)
None
 0.47A 1iepA-2og8A:
27.0		 1iepA-2og8A:
45.30
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
1IEP_B_STIB202_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL)		 2og8 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE LCK
(Homo
sapiens) 		9 / 12 LEU A 251
VAL A 259
ALA A 271
GLU A 288
MET A 292
THR A 316
GLY A 322
ALA A 381
ASP A 382
 None
None
1N8  A 501 ( 3.4A)
1N8  A 501 ( 3.6A)
1N8  A 501 ( 3.6A)
1N8  A 501 ( 3.3A)
1N8  A 501 ( 3.5A)
1N8  A 501 ( 3.3A)
1N8  A 501 ( 3.3A)
 0.71A 1iepB-2og8A:
27.0		 1iepB-2og8A:
45.30
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
1IEP_B_STIB202_2
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL)		 2og8 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE LCK
(Homo
sapiens) 		4 / 7 VAL A 301
ILE A 314
MET A 319
LEU A 371
 None
1N8  A 501 ( 4.6A)
1N8  A 501 ( 4.4A)
1N8  A 501 ( 4.3A)
 0.59A 1iepB-2og8A:
27.0		 1iepB-2og8A:
45.30
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
1IEP_B_STIB202_2
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL)		 2og8 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE LCK
(Homo
sapiens) 		4 / 7 VAL A 301
MET A 319
ARG A 363
LEU A 371
 None
1N8  A 501 ( 4.4A)
None
1N8  A 501 ( 4.3A)
 0.70A 1iepB-2og8A:
27.0		 1iepB-2og8A:
45.30
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
1M17_A_AQ4A999_1
(EPIDERMAL GROWTH
FACTOR RECEPTOR)		 2og8 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE LCK
(Homo
sapiens) 		8 / 12 LEU A 251
ALA A 271
LYS A 273
GLU A 288
THR A 316
MET A 319
GLY A 322
LEU A 371
 None
1N8  A 501 ( 3.4A)
1N8  A 501 ( 3.4A)
1N8  A 501 ( 3.6A)
1N8  A 501 ( 3.3A)
1N8  A 501 ( 4.4A)
1N8  A 501 ( 3.5A)
1N8  A 501 ( 4.3A)
 0.76A 1m17A-2og8A:
24.2		 1m17A-2og8A:
33.43
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1MUO_A_ADNA1_1
(AURORA-RELATED
KINASE 1)		 2og8 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE LCK
(Homo
sapiens) 		6 / 9 LEU A 251
GLY A 252
VAL A 259
ALA A 271
LEU A 371
TYR A 318
 None
None
None
1N8  A 501 ( 3.4A)
1N8  A 501 ( 4.3A)
1N8  A 501 ( 3.7A)
 1.03A 1muoA-2og8A:
8.7		 1muoA-2og8A:
28.72
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
1OPJ_A_STIA3_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1)		 2og8 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE LCK
(Homo
sapiens) 		10 / 12 LEU A 251
VAL A 259
ALA A 271
GLU A 288
MET A 292
VAL A 301
THR A 316
LEU A 371
ALA A 381
ASP A 382
 None
None
1N8  A 501 ( 3.4A)
1N8  A 501 ( 3.6A)
1N8  A 501 ( 3.6A)
None
1N8  A 501 ( 3.3A)
1N8  A 501 ( 4.3A)
1N8  A 501 ( 3.3A)
1N8  A 501 ( 3.3A)
 0.66A 1opjA-2og8A:
26.1		 1opjA-2og8A:
45.30
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
1OPJ_B_STIB4_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1)		 2og8 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE LCK
(Homo
sapiens) 		9 / 12 VAL A 259
ALA A 271
GLU A 288
MET A 292
VAL A 301
THR A 316
GLY A 322
ALA A 381
ASP A 382
 None
1N8  A 501 ( 3.4A)
1N8  A 501 ( 3.6A)
1N8  A 501 ( 3.6A)
None
1N8  A 501 ( 3.3A)
1N8  A 501 ( 3.5A)
1N8  A 501 ( 3.3A)
1N8  A 501 ( 3.3A)
 0.52A 1opjB-2og8A:
31.9		 1opjB-2og8A:
45.30
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
1OPJ_B_STIB4_2
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1)		 2og8 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE LCK
(Homo
sapiens) 		4 / 6 LEU A 251
ILE A 314
MET A 319
ARG A 363
 None
1N8  A 501 ( 4.6A)
1N8  A 501 ( 4.4A)
None
 0.56A 1opjB-2og8A:
31.9		 1opjB-2og8A:
45.30
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
1OPJ_B_STIB4_2
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1)		 2og8 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE LCK
(Homo
sapiens) 		4 / 6 LEU A 251
LYS A 273
ILE A 314
ARG A 363
 None
1N8  A 501 ( 3.4A)
1N8  A 501 ( 4.6A)
None
 1.00A 1opjB-2og8A:
31.9		 1opjB-2og8A:
45.30
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
1T46_A_STIA3_1
(HOMO SAPIENS V-KIT
HARDY-ZUCKERMAN 4
FELINE SARCOMA VIRAL
ONCOGENE HOMOLOG)		 2og8 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE LCK
(Homo
sapiens) 		8 / 12 ALA A 271
LYS A 273
GLU A 288
THR A 316
GLY A 322
LEU A 371
ASP A 382
PHE A 383
 1N8  A 501 ( 3.4A)
1N8  A 501 ( 3.4A)
1N8  A 501 ( 3.6A)
1N8  A 501 ( 3.3A)
1N8  A 501 ( 3.5A)
1N8  A 501 ( 4.3A)
1N8  A 501 ( 3.3A)
1N8  A 501 ( 4.3A)
 0.83A 1t46A-2og8A:
31.4		 1t46A-2og8A:
37.86
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
1T46_A_STIA3_1
(HOMO SAPIENS V-KIT
HARDY-ZUCKERMAN 4
FELINE SARCOMA VIRAL
ONCOGENE HOMOLOG)		 2og8 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE LCK
(Homo
sapiens) 		8 / 12 ALA A 271
LYS A 273
GLU A 288
VAL A 301
THR A 316
GLY A 322
LEU A 371
ASP A 382
 1N8  A 501 ( 3.4A)
1N8  A 501 ( 3.4A)
1N8  A 501 ( 3.6A)
None
1N8  A 501 ( 3.3A)
1N8  A 501 ( 3.5A)
1N8  A 501 ( 4.3A)
1N8  A 501 ( 3.3A)
 0.53A 1t46A-2og8A:
31.4		 1t46A-2og8A:
37.86
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
1T46_A_STIA3_1
(HOMO SAPIENS V-KIT
HARDY-ZUCKERMAN 4
FELINE SARCOMA VIRAL
ONCOGENE HOMOLOG)		 2og8 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE LCK
(Homo
sapiens) 		8 / 12 LEU A 251
ALA A 271
LYS A 273
GLU A 288
VAL A 301
THR A 316
GLY A 322
ASP A 382
 None
1N8  A 501 ( 3.4A)
1N8  A 501 ( 3.4A)
1N8  A 501 ( 3.6A)
None
1N8  A 501 ( 3.3A)
1N8  A 501 ( 3.5A)
1N8  A 501 ( 3.3A)
 0.65A 1t46A-2og8A:
31.4		 1t46A-2og8A:
37.86
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
1T46_A_STIA3_1
(HOMO SAPIENS V-KIT
HARDY-ZUCKERMAN 4
FELINE SARCOMA VIRAL
ONCOGENE HOMOLOG)		 2og8 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE LCK
(Homo
sapiens) 		9 / 12 LEU A 251
VAL A 259
ALA A 271
LYS A 273
GLU A 288
THR A 316
GLY A 322
ASP A 382
PHE A 383
 None
None
1N8  A 501 ( 3.4A)
1N8  A 501 ( 3.4A)
1N8  A 501 ( 3.6A)
1N8  A 501 ( 3.3A)
1N8  A 501 ( 3.5A)
1N8  A 501 ( 3.3A)
1N8  A 501 ( 4.3A)
 1.06A 1t46A-2og8A:
31.4		 1t46A-2og8A:
37.86
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
1UWJ_A_BAXA1723_1
(B-RAF PROTO-ONCOGENE
SERINE/THREONINE-PRO
TEIN KINASE)		 2og8 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE LCK
(Homo
sapiens) 		5 / 12 VAL A 259
ALA A 271
GLU A 288
THR A 316
HIS A 362
 None
1N8  A 501 ( 3.4A)
1N8  A 501 ( 3.6A)
1N8  A 501 ( 3.3A)
None
 0.51A 1uwjA-2og8A:
8.1		 1uwjA-2og8A:
33.92
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
1UWJ_B_BAXB1723_1
(B-RAF PROTO-ONCOGENE
SERINE/THREONINE-PRO
TEIN KINASE)		 2og8 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE LCK
(Homo
sapiens) 		5 / 12 VAL A 259
ALA A 271
GLU A 288
THR A 316
HIS A 362
 None
1N8  A 501 ( 3.4A)
1N8  A 501 ( 3.6A)
1N8  A 501 ( 3.3A)
None
 0.51A 1uwjB-2og8A:
8.0		 1uwjB-2og8A:
33.92
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
1XKK_A_FMMA91_1
(EPIDERMAL GROWTH
FACTOR RECEPTOR)		 2og8 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE LCK
(Homo
sapiens) 		5 / 12 ALA A 271
THR A 316
GLY A 322
ASP A 326
LEU A 371
 1N8  A 501 ( 3.4A)
1N8  A 501 ( 3.3A)
1N8  A 501 ( 3.5A)
None
1N8  A 501 ( 4.3A)
 0.48A 1xkkA-2og8A:
24.9		 1xkkA-2og8A:
33.14
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2GQG_A_1N1A501_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1)		 2og8 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE LCK
(Homo
sapiens) 		9 / 12 LEU A 251
ALA A 271
GLU A 288
MET A 292
VAL A 301
ILE A 314
THR A 316
GLY A 322
LEU A 371
 None
1N8  A 501 ( 3.4A)
1N8  A 501 ( 3.6A)
1N8  A 501 ( 3.6A)
None
1N8  A 501 ( 4.6A)
1N8  A 501 ( 3.3A)
1N8  A 501 ( 3.5A)
1N8  A 501 ( 4.3A)
 0.88A 2gqgA-2og8A:
31.5		 2gqgA-2og8A:
47.97
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2GQG_A_1N1A501_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1)		 2og8 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE LCK
(Homo
sapiens) 		9 / 12 LEU A 251
ALA A 271
LYS A 273
GLU A 288
MET A 292
ILE A 314
THR A 316
GLY A 322
LEU A 371
 None
1N8  A 501 ( 3.4A)
1N8  A 501 ( 3.4A)
1N8  A 501 ( 3.6A)
1N8  A 501 ( 3.6A)
1N8  A 501 ( 4.6A)
1N8  A 501 ( 3.3A)
1N8  A 501 ( 3.5A)
1N8  A 501 ( 4.3A)
 0.97A 2gqgA-2og8A:
31.5		 2gqgA-2og8A:
47.97
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2GQG_A_1N1A501_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1)		 2og8 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE LCK
(Homo
sapiens) 		9 / 12 LEU A 251
ALA A 271
LYS A 273
MET A 292
ILE A 314
THR A 316
GLY A 322
LEU A 371
ALA A 381
 None
1N8  A 501 ( 3.4A)
1N8  A 501 ( 3.4A)
1N8  A 501 ( 3.6A)
1N8  A 501 ( 4.6A)
1N8  A 501 ( 3.3A)
1N8  A 501 ( 3.5A)
1N8  A 501 ( 4.3A)
1N8  A 501 ( 3.3A)
 0.84A 2gqgA-2og8A:
31.5		 2gqgA-2og8A:
47.97
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2GQG_A_1N1A501_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1)		 2og8 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE LCK
(Homo
sapiens) 		9 / 12 LEU A 251
ALA A 271
MET A 292
VAL A 301
ILE A 314
THR A 316
GLY A 322
LEU A 371
ALA A 381
 None
1N8  A 501 ( 3.4A)
1N8  A 501 ( 3.6A)
None
1N8  A 501 ( 4.6A)
1N8  A 501 ( 3.3A)
1N8  A 501 ( 3.5A)
1N8  A 501 ( 4.3A)
1N8  A 501 ( 3.3A)
 0.74A 2gqgA-2og8A:
31.5		 2gqgA-2og8A:
47.97
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2GQG_B_1N1B502_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1)		 2og8 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE LCK
(Homo
sapiens) 		9 / 12 ALA A 271
GLU A 288
MET A 292
VAL A 301
ILE A 314
THR A 316
GLY A 322
LEU A 371
ALA A 381
 1N8  A 501 ( 3.4A)
1N8  A 501 ( 3.6A)
1N8  A 501 ( 3.6A)
None
1N8  A 501 ( 4.6A)
1N8  A 501 ( 3.3A)
1N8  A 501 ( 3.5A)
1N8  A 501 ( 4.3A)
1N8  A 501 ( 3.3A)
 0.65A 2gqgB-2og8A:
31.5		 2gqgB-2og8A:
47.97
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2GQG_B_1N1B502_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1)		 2og8 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE LCK
(Homo
sapiens) 		8 / 12 LEU A 251
ALA A 271
GLU A 288
MET A 292
VAL A 301
ILE A 314
THR A 316
ALA A 381
 None
1N8  A 501 ( 3.4A)
1N8  A 501 ( 3.6A)
1N8  A 501 ( 3.6A)
None
1N8  A 501 ( 4.6A)
1N8  A 501 ( 3.3A)
1N8  A 501 ( 3.3A)
 0.57A 2gqgB-2og8A:
31.5		 2gqgB-2og8A:
47.97
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2GQG_B_1N1B502_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1)		 2og8 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE LCK
(Homo
sapiens) 		8 / 12 LEU A 251
VAL A 259
ALA A 271
GLU A 288
MET A 292
VAL A 301
ILE A 314
THR A 316
 None
None
1N8  A 501 ( 3.4A)
1N8  A 501 ( 3.6A)
1N8  A 501 ( 3.6A)
None
1N8  A 501 ( 4.6A)
1N8  A 501 ( 3.3A)
 0.49A 2gqgB-2og8A:
31.5		 2gqgB-2og8A:
47.97
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2HYY_A_STIA600_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1)		 2og8 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE LCK
(Homo
sapiens) 		9 / 12 VAL A 259
ALA A 271
GLU A 288
MET A 292
THR A 316
GLY A 322
LEU A 371
ALA A 381
ASP A 382
 None
1N8  A 501 ( 3.4A)
1N8  A 501 ( 3.6A)
1N8  A 501 ( 3.6A)
1N8  A 501 ( 3.3A)
1N8  A 501 ( 3.5A)
1N8  A 501 ( 4.3A)
1N8  A 501 ( 3.3A)
1N8  A 501 ( 3.3A)
 0.55A 2hyyA-2og8A:
32.5		 2hyyA-2og8A:
47.97
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2HYY_A_STIA600_2
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1)		 2og8 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE LCK
(Homo
sapiens) 		4 / 6 LEU A 251
VAL A 301
ILE A 314
ARG A 363
 None
None
1N8  A 501 ( 4.6A)
None
 0.68A 2hyyA-2og8A:
32.5		 2hyyA-2og8A:
47.97
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2HYY_B_STIB600_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1)		 2og8 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE LCK
(Homo
sapiens) 		9 / 12 VAL A 259
ALA A 271
GLU A 288
MET A 292
THR A 316
GLY A 322
LEU A 371
ALA A 381
ASP A 382
 None
1N8  A 501 ( 3.4A)
1N8  A 501 ( 3.6A)
1N8  A 501 ( 3.6A)
1N8  A 501 ( 3.3A)
1N8  A 501 ( 3.5A)
1N8  A 501 ( 4.3A)
1N8  A 501 ( 3.3A)
1N8  A 501 ( 3.3A)
 0.55A 2hyyB-2og8A:
32.3		 2hyyB-2og8A:
47.97
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2HYY_B_STIB600_2
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1)		 2og8 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE LCK
(Homo
sapiens) 		4 / 6 LEU A 251
VAL A 301
ILE A 314
MET A 319
 None
None
1N8  A 501 ( 4.6A)
1N8  A 501 ( 4.4A)
 0.67A 2hyyB-2og8A:
32.6		 2hyyB-2og8A:
47.97
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2HYY_C_STIC600_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1)		 2og8 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE LCK
(Homo
sapiens) 		9 / 12 VAL A 259
ALA A 271
GLU A 288
VAL A 301
THR A 316
GLY A 322
LEU A 371
ALA A 381
ASP A 382
 None
1N8  A 501 ( 3.4A)
1N8  A 501 ( 3.6A)
None
1N8  A 501 ( 3.3A)
1N8  A 501 ( 3.5A)
1N8  A 501 ( 4.3A)
1N8  A 501 ( 3.3A)
1N8  A 501 ( 3.3A)
 0.54A 2hyyC-2og8A:
32.6		 2hyyC-2og8A:
47.97
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2HYY_C_STIC600_2
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1)		 2og8 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE LCK
(Homo
sapiens) 		4 / 6 LEU A 251
LYS A 273
MET A 292
ILE A 314
 None
1N8  A 501 ( 3.4A)
1N8  A 501 ( 3.6A)
1N8  A 501 ( 4.6A)
 0.99A 2hyyC-2og8A:
32.6		 2hyyC-2og8A:
47.97
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2HYY_C_STIC600_2
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1)		 2og8 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE LCK
(Homo
sapiens) 		4 / 6 LEU A 251
MET A 292
ILE A 314
MET A 319
 None
1N8  A 501 ( 3.6A)
1N8  A 501 ( 4.6A)
1N8  A 501 ( 4.4A)
 0.71A 2hyyC-2og8A:
32.6		 2hyyC-2og8A:
47.97
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2HYY_D_STID600_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1)		 2og8 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE LCK
(Homo
sapiens) 		9 / 12 VAL A 259
ALA A 271
GLU A 288
MET A 292
ILE A 314
THR A 316
LEU A 371
ALA A 381
ASP A 382
 None
1N8  A 501 ( 3.4A)
1N8  A 501 ( 3.6A)
1N8  A 501 ( 3.6A)
1N8  A 501 ( 4.6A)
1N8  A 501 ( 3.3A)
1N8  A 501 ( 4.3A)
1N8  A 501 ( 3.3A)
1N8  A 501 ( 3.3A)
 0.56A 2hyyD-2og8A:
32.5		 2hyyD-2og8A:
47.97
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2ITO_A_IREA2020_1
(EPIDERMAL GROWTH
FACTOR RECEPTOR)		 2og8 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE LCK
(Homo
sapiens) 		9 / 12 LEU A 251
ALA A 271
LYS A 273
GLU A 288
MET A 292
THR A 316
GLY A 322
ASP A 326
LEU A 371
 None
1N8  A 501 ( 3.4A)
1N8  A 501 ( 3.4A)
1N8  A 501 ( 3.6A)
1N8  A 501 ( 3.6A)
1N8  A 501 ( 3.3A)
1N8  A 501 ( 3.5A)
None
1N8  A 501 ( 4.3A)
 0.93A 2itoA-2og8A:
29.8		 2itoA-2og8A:
33.44
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2ITY_A_IREA2020_1
(EPIDERMAL GROWTH
FACTOR RECEPTOR)		 2og8 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE LCK
(Homo
sapiens) 		8 / 12 LEU A 251
GLY A 252
VAL A 259
ALA A 271
LYS A 273
GLU A 288
MET A 292
THR A 316
 None
None
None
1N8  A 501 ( 3.4A)
1N8  A 501 ( 3.4A)
1N8  A 501 ( 3.6A)
1N8  A 501 ( 3.6A)
1N8  A 501 ( 3.3A)
 0.69A 2ityA-2og8A:
29.9		 2ityA-2og8A:
33.75
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2ITZ_A_IREA2021_1
(EPIDERMAL GROWTH
FACTOR RECEPTOR)		 2og8 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE LCK
(Homo
sapiens) 		10 / 12 LEU A 251
VAL A 259
ALA A 271
LYS A 273
GLU A 288
MET A 292
THR A 316
GLY A 322
ASP A 326
LEU A 371
 None
None
1N8  A 501 ( 3.4A)
1N8  A 501 ( 3.4A)
1N8  A 501 ( 3.6A)
1N8  A 501 ( 3.6A)
1N8  A 501 ( 3.3A)
1N8  A 501 ( 3.5A)
None
1N8  A 501 ( 4.3A)
 1.00A 2itzA-2og8A:
29.5		 2itzA-2og8A:
33.44
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2OIQ_A_STIA1001_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE SRC)		 2og8 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE LCK
(Homo
sapiens) 		11 / 12 VAL A 259
ALA A 271
GLU A 288
MET A 292
ILE A 314
THR A 316
TYR A 318
GLY A 322
LEU A 371
ALA A 381
ASP A 382
 None
1N8  A 501 ( 3.4A)
1N8  A 501 ( 3.6A)
1N8  A 501 ( 3.6A)
1N8  A 501 ( 4.6A)
1N8  A 501 ( 3.3A)
1N8  A 501 ( 3.7A)
1N8  A 501 ( 3.5A)
1N8  A 501 ( 4.3A)
1N8  A 501 ( 3.3A)
1N8  A 501 ( 3.3A)
 0.47A 2oiqA-2og8A:
29.3		 2oiqA-2og8A:
67.55
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2OIQ_A_STIA1001_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE SRC)		 2og8 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE LCK
(Homo
sapiens) 		7 / 12 VAL A 259
ALA A 271
LYS A 273
GLU A 288
MET A 292
ILE A 314
ASP A 382
 None
1N8  A 501 ( 3.4A)
1N8  A 501 ( 3.4A)
1N8  A 501 ( 3.6A)
1N8  A 501 ( 3.6A)
1N8  A 501 ( 4.6A)
1N8  A 501 ( 3.3A)
 0.74A 2oiqA-2og8A:
29.3		 2oiqA-2og8A:
67.55
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2OIQ_A_STIA1001_2
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE SRC)		 2og8 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE LCK
(Homo
sapiens) 		4 / 5 LEU A 251
LEU A 295
MET A 319
ARG A 363
 None
1N8  A 501 ( 3.9A)
1N8  A 501 ( 4.4A)
None
 0.73A 2oiqA-2og8A:
29.3		 2oiqA-2og8A:
67.55
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2PL0_A_STIA200_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE LCK)		 2og8 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE LCK
(Homo
sapiens) 		11 / 12 VAL A 259
ALA A 271
GLU A 288
MET A 292
VAL A 301
ILE A 314
THR A 316
TYR A 318
LEU A 371
ALA A 381
ASP A 382
 None
1N8  A 501 ( 3.4A)
1N8  A 501 ( 3.6A)
1N8  A 501 ( 3.6A)
None
1N8  A 501 ( 4.6A)
1N8  A 501 ( 3.3A)
1N8  A 501 ( 3.7A)
1N8  A 501 ( 4.3A)
1N8  A 501 ( 3.3A)
1N8  A 501 ( 3.3A)
 0.44A 2pl0A-2og8A:
37.6		 2pl0A-2og8A:
100.00
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2PL0_A_STIA200_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE LCK)		 2og8 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE LCK
(Homo
sapiens) 		9 / 12 VAL A 259
ALA A 271
LYS A 273
GLU A 288
MET A 292
ILE A 314
TYR A 318
ALA A 381
ASP A 382
 None
1N8  A 501 ( 3.4A)
1N8  A 501 ( 3.4A)
1N8  A 501 ( 3.6A)
1N8  A 501 ( 3.6A)
1N8  A 501 ( 4.6A)
1N8  A 501 ( 3.7A)
1N8  A 501 ( 3.3A)
1N8  A 501 ( 3.3A)
 0.64A 2pl0A-2og8A:
37.6		 2pl0A-2og8A:
100.00
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2WGJ_A_VGHA2346_1
(HEPATOCYTE GROWTH
FACTOR RECEPTOR)		 2og8 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE LCK
(Homo
sapiens) 		6 / 12 VAL A 259
ALA A 271
TYR A 318
MET A 319
GLY A 322
ALA A 381
 None
1N8  A 501 ( 3.4A)
1N8  A 501 ( 3.7A)
1N8  A 501 ( 4.4A)
1N8  A 501 ( 3.5A)
1N8  A 501 ( 3.3A)
 0.59A 2wgjA-2og8A:
30.0		 2wgjA-2og8A:
34.35
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2XP2_A_VGHA9000_1
(TYROSINE-PROTEIN
KINASE RECEPTOR)		 2og8 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE LCK
(Homo
sapiens) 		6 / 9 LEU A 251
VAL A 259
ALA A 271
MET A 319
GLY A 322
LEU A 371
 None
None
1N8  A 501 ( 3.4A)
1N8  A 501 ( 4.4A)
1N8  A 501 ( 3.5A)
1N8  A 501 ( 4.3A)
 0.81A 2xp2A-2og8A:
30.5		 2xp2A-2og8A:
40.14
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2Y6O_A_1N1A1892_1
(EPHRIN TYPE-A
RECEPTOR 4)		 2og8 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE LCK
(Homo
sapiens) 		9 / 12 ALA A 271
LYS A 273
GLU A 288
MET A 292
ILE A 314
THR A 316
TYR A 318
GLY A 322
LEU A 371
 1N8  A 501 ( 3.4A)
1N8  A 501 ( 3.4A)
1N8  A 501 ( 3.6A)
1N8  A 501 ( 3.6A)
1N8  A 501 ( 4.6A)
1N8  A 501 ( 3.3A)
1N8  A 501 ( 3.7A)
1N8  A 501 ( 3.5A)
1N8  A 501 ( 4.3A)
 0.67A 2y6oA-2og8A:
33.2		 2y6oA-2og8A:
43.10
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2YFX_A_VGHA9000_1
(TYROSINE-PROTEIN
KINASE RECEPTOR)		 2og8 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE LCK
(Homo
sapiens) 		5 / 8 LEU A 251
ALA A 271
MET A 319
GLY A 322
LEU A 371
 None
1N8  A 501 ( 3.4A)
1N8  A 501 ( 4.4A)
1N8  A 501 ( 3.5A)
1N8  A 501 ( 4.3A)
 0.63A 2yfxA-2og8A:
30.0		 2yfxA-2og8A:
40.14
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2ZVA_A_1N1A513_1
(TYROSINE-PROTEIN
KINASE LYN)		 2og8 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE LCK
(Homo
sapiens) 		12 / 12 LEU A 251
ALA A 271
LYS A 273
GLU A 288
MET A 292
VAL A 301
ILE A 314
THR A 316
MET A 319
GLY A 322
LEU A 371
ALA A 381
 None
1N8  A 501 ( 3.4A)
1N8  A 501 ( 3.4A)
1N8  A 501 ( 3.6A)
1N8  A 501 ( 3.6A)
None
1N8  A 501 ( 4.6A)
1N8  A 501 ( 3.3A)
1N8  A 501 ( 4.4A)
1N8  A 501 ( 3.5A)
1N8  A 501 ( 4.3A)
1N8  A 501 ( 3.3A)
 0.87A 2zvaA-2og8A:
35.7		 2zvaA-2og8A:
73.41
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3AOX_A_EMHA901_1
(ALK TYROSINE KINASE
RECEPTOR)		 2og8 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE LCK
(Homo
sapiens) 		7 / 10 LEU A 251
ALA A 271
LYS A 273
VAL A 301
MET A 319
GLY A 322
LEU A 371
 None
1N8  A 501 ( 3.4A)
1N8  A 501 ( 3.4A)
None
1N8  A 501 ( 4.4A)
1N8  A 501 ( 3.5A)
1N8  A 501 ( 4.3A)
 0.93A 3aoxA-2og8A:
29.4		 3aoxA-2og8A:
40.14
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3CS9_A_NILA600_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1)		 2og8 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE LCK
(Homo
sapiens) 		5 / 10 LEU A 251
VAL A 259
LYS A 273
ILE A 314
ASP A 382
 None
None
1N8  A 501 ( 3.4A)
1N8  A 501 ( 4.6A)
1N8  A 501 ( 3.3A)
 0.91A 3cs9A-2og8A:
32.4		 3cs9A-2og8A:
47.97
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3CS9_A_NILA600_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1)		 2og8 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE LCK
(Homo
sapiens) 		5 / 10 LEU A 251
VAL A 259
VAL A 301
ILE A 314
ASP A 382
 None
None
None
1N8  A 501 ( 4.6A)
1N8  A 501 ( 3.3A)
 0.57A 3cs9A-2og8A:
32.4		 3cs9A-2og8A:
47.97
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3CS9_A_NILA600_2
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1)		 2og8 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE LCK
(Homo
sapiens) 		9 / 12 ALA A 271
GLU A 288
MET A 292
LEU A 300
THR A 316
GLY A 322
HIS A 362
LEU A 371
ALA A 381
 1N8  A 501 ( 3.4A)
1N8  A 501 ( 3.6A)
1N8  A 501 ( 3.6A)
1N8  A 501 ( 3.9A)
1N8  A 501 ( 3.3A)
1N8  A 501 ( 3.5A)
None
1N8  A 501 ( 4.3A)
1N8  A 501 ( 3.3A)
 0.46A 3cs9A-2og8A:
32.4		 3cs9A-2og8A:
47.97
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3CS9_B_NILB600_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1)		 2og8 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE LCK
(Homo
sapiens) 		10 / 12 ALA A 271
GLU A 288
MET A 292
LEU A 300
THR A 316
GLY A 322
HIS A 362
ALA A 381
ASP A 382
PHE A 383
 1N8  A 501 ( 3.4A)
1N8  A 501 ( 3.6A)
1N8  A 501 ( 3.6A)
1N8  A 501 ( 3.9A)
1N8  A 501 ( 3.3A)
1N8  A 501 ( 3.5A)
None
1N8  A 501 ( 3.3A)
1N8  A 501 ( 3.3A)
1N8  A 501 ( 4.3A)
 0.51A 3cs9B-2og8A:
32.8		 3cs9B-2og8A:
47.97
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3CS9_B_NILB600_2
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1)		 2og8 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE LCK
(Homo
sapiens) 		5 / 9 LEU A 251
VAL A 259
VAL A 301
ILE A 314
LEU A 371
 None
None
None
1N8  A 501 ( 4.6A)
1N8  A 501 ( 4.3A)
 0.75A 3cs9B-2og8A:
33.0		 3cs9B-2og8A:
47.97
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3CS9_C_NILC600_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1)		 2og8 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE LCK
(Homo
sapiens) 		8 / 12 ALA A 271
GLU A 288
MET A 292
LEU A 300
THR A 316
HIS A 362
ALA A 381
ASP A 382
 1N8  A 501 ( 3.4A)
1N8  A 501 ( 3.6A)
1N8  A 501 ( 3.6A)
1N8  A 501 ( 3.9A)
1N8  A 501 ( 3.3A)
None
1N8  A 501 ( 3.3A)
1N8  A 501 ( 3.3A)
 0.46A 3cs9C-2og8A:
32.6		 3cs9C-2og8A:
47.97
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3CS9_C_NILC600_2
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1)		 2og8 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE LCK
(Homo
sapiens) 		5 / 9 LEU A 251
VAL A 259
LYS A 273
ILE A 314
PHE A 383
 None
None
1N8  A 501 ( 3.4A)
1N8  A 501 ( 4.6A)
1N8  A 501 ( 4.3A)
 0.83A 3cs9C-2og8A:
32.6		 3cs9C-2og8A:
47.97
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3CS9_C_NILC600_2
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1)		 2og8 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE LCK
(Homo
sapiens) 		6 / 9 LEU A 251
VAL A 259
VAL A 301
ILE A 314
MET A 319
PHE A 383
 None
None
None
1N8  A 501 ( 4.6A)
1N8  A 501 ( 4.4A)
1N8  A 501 ( 4.3A)
 0.57A 3cs9C-2og8A:
32.6		 3cs9C-2og8A:
47.97
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3CS9_D_NILD600_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1)		 2og8 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE LCK
(Homo
sapiens) 		8 / 12 ALA A 271
GLU A 288
MET A 292
LEU A 300
THR A 316
GLY A 322
HIS A 362
ALA A 381
 1N8  A 501 ( 3.4A)
1N8  A 501 ( 3.6A)
1N8  A 501 ( 3.6A)
1N8  A 501 ( 3.9A)
1N8  A 501 ( 3.3A)
1N8  A 501 ( 3.5A)
None
1N8  A 501 ( 3.3A)
 0.45A 3cs9D-2og8A:
26.6		 3cs9D-2og8A:
47.97
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3CS9_D_NILD600_2
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1)		 2og8 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE LCK
(Homo
sapiens) 		5 / 6 LEU A 251
VAL A 259
LYS A 273
LEU A 371
ASP A 382
 None
None
1N8  A 501 ( 3.4A)
1N8  A 501 ( 4.3A)
1N8  A 501 ( 3.3A)
 0.97A 3cs9D-2og8A:
26.6		 3cs9D-2og8A:
47.97
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3G0F_A_B49A9001_1
(MAST/STEM CELL
GROWTH FACTOR
RECEPTOR)		 2og8 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE LCK
(Homo
sapiens) 		7 / 11 LEU A 251
VAL A 259
ALA A 271
THR A 316
TYR A 318
GLY A 322
PHE A 383
 None
None
1N8  A 501 ( 3.4A)
1N8  A 501 ( 3.3A)
1N8  A 501 ( 3.7A)
1N8  A 501 ( 3.5A)
1N8  A 501 ( 4.3A)
 1.04A 3g0fA-2og8A:
16.6		 3g0fA-2og8A:
34.51
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3G0F_A_B49A9001_1
(MAST/STEM CELL
GROWTH FACTOR
RECEPTOR)		 2og8 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE LCK
(Homo
sapiens) 		7 / 11 VAL A 259
ALA A 271
THR A 316
TYR A 318
GLY A 322
LEU A 371
PHE A 383
 None
1N8  A 501 ( 3.4A)
1N8  A 501 ( 3.3A)
1N8  A 501 ( 3.7A)
1N8  A 501 ( 3.5A)
1N8  A 501 ( 4.3A)
1N8  A 501 ( 4.3A)
 0.99A 3g0fA-2og8A:
16.6		 3g0fA-2og8A:
34.51
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3G0F_B_B49B9001_1
(MAST/STEM CELL
GROWTH FACTOR
RECEPTOR)		 2og8 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE LCK
(Homo
sapiens) 		7 / 10 LEU A 251
VAL A 259
ALA A 271
THR A 316
TYR A 318
GLY A 322
PHE A 383
 None
None
1N8  A 501 ( 3.4A)
1N8  A 501 ( 3.3A)
1N8  A 501 ( 3.7A)
1N8  A 501 ( 3.5A)
1N8  A 501 ( 4.3A)
 1.14A 3g0fB-2og8A:
30.3		 3g0fB-2og8A:
34.51
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3G0F_B_B49B9001_1
(MAST/STEM CELL
GROWTH FACTOR
RECEPTOR)		 2og8 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE LCK
(Homo
sapiens) 		7 / 10 VAL A 259
ALA A 271
THR A 316
TYR A 318
GLY A 322
LEU A 371
PHE A 383
 None
1N8  A 501 ( 3.4A)
1N8  A 501 ( 3.3A)
1N8  A 501 ( 3.7A)
1N8  A 501 ( 3.5A)
1N8  A 501 ( 4.3A)
1N8  A 501 ( 4.3A)
 1.07A 3g0fB-2og8A:
30.3		 3g0fB-2og8A:
34.51
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3G5D_A_1N1A1_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE SRC)		 2og8 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE LCK
(Homo
sapiens) 		10 / 12 ALA A 271
GLU A 288
MET A 292
VAL A 301
ILE A 314
THR A 316
TYR A 318
GLY A 322
LEU A 371
ALA A 381
 1N8  A 501 ( 3.4A)
1N8  A 501 ( 3.6A)
1N8  A 501 ( 3.6A)
None
1N8  A 501 ( 4.6A)
1N8  A 501 ( 3.3A)
1N8  A 501 ( 3.7A)
1N8  A 501 ( 3.5A)
1N8  A 501 ( 4.3A)
1N8  A 501 ( 3.3A)
 0.72A 3g5dA-2og8A:
34.1		 3g5dA-2og8A:
67.17
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3G5D_A_1N1A1_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE SRC)		 2og8 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE LCK
(Homo
sapiens) 		9 / 12 LEU A 251
ALA A 271
GLU A 288
MET A 292
VAL A 301
ILE A 314
THR A 316
TYR A 318
ALA A 381
 None
1N8  A 501 ( 3.4A)
1N8  A 501 ( 3.6A)
1N8  A 501 ( 3.6A)
None
1N8  A 501 ( 4.6A)
1N8  A 501 ( 3.3A)
1N8  A 501 ( 3.7A)
1N8  A 501 ( 3.3A)
 0.53A 3g5dA-2og8A:
34.1		 3g5dA-2og8A:
67.17
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3G5D_A_1N1A1_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE SRC)		 2og8 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE LCK
(Homo
sapiens) 		8 / 12 LEU A 251
VAL A 259
ALA A 271
GLU A 288
MET A 292
ILE A 314
THR A 316
TYR A 318
 None
None
1N8  A 501 ( 3.4A)
1N8  A 501 ( 3.6A)
1N8  A 501 ( 3.6A)
1N8  A 501 ( 4.6A)
1N8  A 501 ( 3.3A)
1N8  A 501 ( 3.7A)
 0.47A 3g5dA-2og8A:
34.1		 3g5dA-2og8A:
67.17
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3G5D_B_1N1B1_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE SRC)		 2og8 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE LCK
(Homo
sapiens) 		11 / 12 LEU A 251
ALA A 271
LYS A 273
GLU A 288
MET A 292
VAL A 301
THR A 316
TYR A 318
GLY A 322
LEU A 371
ALA A 381
 None
1N8  A 501 ( 3.4A)
1N8  A 501 ( 3.4A)
1N8  A 501 ( 3.6A)
1N8  A 501 ( 3.6A)
None
1N8  A 501 ( 3.3A)
1N8  A 501 ( 3.7A)
1N8  A 501 ( 3.5A)
1N8  A 501 ( 4.3A)
1N8  A 501 ( 3.3A)
 0.87A 3g5dB-2og8A:
34.3		 3g5dB-2og8A:
67.17
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3G5D_B_1N1B1_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE SRC)		 2og8 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE LCK
(Homo
sapiens) 		10 / 12 LEU A 251
VAL A 259
ALA A 271
LYS A 273
GLU A 288
MET A 292
VAL A 301
THR A 316
TYR A 318
ALA A 381
 None
None
1N8  A 501 ( 3.4A)
1N8  A 501 ( 3.4A)
1N8  A 501 ( 3.6A)
1N8  A 501 ( 3.6A)
None
1N8  A 501 ( 3.3A)
1N8  A 501 ( 3.7A)
1N8  A 501 ( 3.3A)
 0.72A 3g5dB-2og8A:
34.3		 3g5dB-2og8A:
67.17
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3GCS_A_BAXA401_1
(MITOGEN-ACTIVATED
PROTEIN KINASE 14)		 2og8 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE LCK
(Homo
sapiens) 		5 / 12 ALA A 271
GLU A 288
THR A 316
HIS A 362
ASP A 382
 1N8  A 501 ( 3.4A)
1N8  A 501 ( 3.6A)
1N8  A 501 ( 3.3A)
None
1N8  A 501 ( 3.3A)
 0.87A 3gcsA-2og8A:
20.9		 3gcsA-2og8A:
26.59
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3GCS_A_BAXA401_1
(MITOGEN-ACTIVATED
PROTEIN KINASE 14)		 2og8 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE LCK
(Homo
sapiens) 		6 / 12 ALA A 271
LEU A 291
THR A 316
ILE A 355
HIS A 362
ASP A 382
 1N8  A 501 ( 3.4A)
None
1N8  A 501 ( 3.3A)
None
None
1N8  A 501 ( 3.3A)
 0.84A 3gcsA-2og8A:
20.9		 3gcsA-2og8A:
26.59
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3GCS_A_BAXA401_1
(MITOGEN-ACTIVATED
PROTEIN KINASE 14)		 2og8 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE LCK
(Homo
sapiens) 		6 / 12 VAL A 259
ALA A 271
LEU A 291
THR A 316
ILE A 355
HIS A 362
 None
1N8  A 501 ( 3.4A)
None
1N8  A 501 ( 3.3A)
None
None
 0.95A 3gcsA-2og8A:
20.9		 3gcsA-2og8A:
26.59
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3GP0_A_NILA1_1
(MITOGEN-ACTIVATED
PROTEIN KINASE 11)		 2og8 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE LCK
(Homo
sapiens) 		7 / 12 VAL A 259
ALA A 271
GLU A 288
LEU A 291
THR A 316
HIS A 362
ASP A 382
 None
1N8  A 501 ( 3.4A)
1N8  A 501 ( 3.6A)
None
1N8  A 501 ( 3.3A)
None
1N8  A 501 ( 3.3A)
 0.53A 3gp0A-2og8A:
22.1		 3gp0A-2og8A:
27.02
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3GVU_A_STIA1001_1
(TYROSINE-PROTEIN
KINASE ABL2)		 2og8 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE LCK
(Homo
sapiens) 		10 / 12 LEU A 251
VAL A 259
ALA A 271
GLU A 288
MET A 292
VAL A 301
THR A 316
LEU A 371
ALA A 381
ASP A 382
 None
None
1N8  A 501 ( 3.4A)
1N8  A 501 ( 3.6A)
1N8  A 501 ( 3.6A)
None
1N8  A 501 ( 3.3A)
1N8  A 501 ( 4.3A)
1N8  A 501 ( 3.3A)
1N8  A 501 ( 3.3A)
 0.65A 3gvuA-2og8A:
32.6		 3gvuA-2og8A:
48.71
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3HEC_A_STIA1_1
(MITOGEN-ACTIVATED
PROTEIN KINASE 14)		 2og8 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE LCK
(Homo
sapiens) 		6 / 12 ALA A 271
LYS A 273
GLU A 288
LEU A 291
THR A 316
ASP A 382
 1N8  A 501 ( 3.4A)
1N8  A 501 ( 3.4A)
1N8  A 501 ( 3.6A)
None
1N8  A 501 ( 3.3A)
1N8  A 501 ( 3.3A)
 0.61A 3hecA-2og8A:
18.9		 3hecA-2og8A:
26.57
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3HEG_A_BAXA1_1
(MITOGEN-ACTIVATED
PROTEIN KINASE 14)		 2og8 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE LCK
(Homo
sapiens) 		6 / 12 VAL A 259
ALA A 271
LYS A 273
LEU A 291
THR A 316
ILE A 355
 None
1N8  A 501 ( 3.4A)
1N8  A 501 ( 3.4A)
None
1N8  A 501 ( 3.3A)
None
 1.18A 3hegA-2og8A:
17.8		 3hegA-2og8A:
26.57
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3IK3_A_0LIA1_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1)		 2og8 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE LCK
(Homo
sapiens) 		10 / 12 ALA A 271
GLU A 288
MET A 292
LEU A 300
VAL A 301
HIS A 362
LEU A 371
ALA A 381
ASP A 382
PHE A 383
 1N8  A 501 ( 3.4A)
1N8  A 501 ( 3.6A)
1N8  A 501 ( 3.6A)
1N8  A 501 ( 3.9A)
None
None
1N8  A 501 ( 4.3A)
1N8  A 501 ( 3.3A)
1N8  A 501 ( 3.3A)
1N8  A 501 ( 4.3A)
 0.56A 3ik3A-2og8A:
32.3		 3ik3A-2og8A:
44.95
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3IK3_A_0LIA1_2
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1)		 2og8 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE LCK
(Homo
sapiens) 		4 / 7 LEU A 251
ILE A 314
MET A 319
ARG A 363
 None
1N8  A 501 ( 4.6A)
1N8  A 501 ( 4.4A)
None
 0.77A 3ik3A-2og8A:
32.3		 3ik3A-2og8A:
44.95
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3IK3_B_0LIB2_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1)		 2og8 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE LCK
(Homo
sapiens) 		10 / 12 ALA A 271
GLU A 288
MET A 292
LEU A 300
VAL A 301
HIS A 362
LEU A 371
ALA A 381
ASP A 382
PHE A 383
 1N8  A 501 ( 3.4A)
1N8  A 501 ( 3.6A)
1N8  A 501 ( 3.6A)
1N8  A 501 ( 3.9A)
None
None
1N8  A 501 ( 4.3A)
1N8  A 501 ( 3.3A)
1N8  A 501 ( 3.3A)
1N8  A 501 ( 4.3A)
 0.62A 3ik3B-2og8A:
32.0		 3ik3B-2og8A:
44.95
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3IK3_B_0LIB2_2
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1)		 2og8 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE LCK
(Homo
sapiens) 		4 / 7 LEU A 251
ILE A 314
MET A 319
ARG A 363
 None
1N8  A 501 ( 4.6A)
1N8  A 501 ( 4.4A)
None
 0.81A 3ik3B-2og8A:
32.0		 3ik3B-2og8A:
44.95
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3IK3_B_0LIB2_2
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1)		 2og8 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE LCK
(Homo
sapiens) 		4 / 7 LEU A 251
LYS A 273
ILE A 314
ARG A 363
 None
1N8  A 501 ( 3.4A)
1N8  A 501 ( 4.6A)
None
 1.19A 3ik3B-2og8A:
32.0		 3ik3B-2og8A:
44.95
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3K54_A_1N1A1_1
(TYROSINE-PROTEIN
KINASE BTK)		 2og8 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE LCK
(Homo
sapiens) 		11 / 12 LEU A 251
ALA A 271
LYS A 273
GLU A 288
MET A 292
VAL A 301
ILE A 314
THR A 316
TYR A 318
GLY A 322
LEU A 371
 None
1N8  A 501 ( 3.4A)
1N8  A 501 ( 3.4A)
1N8  A 501 ( 3.6A)
1N8  A 501 ( 3.6A)
None
1N8  A 501 ( 4.6A)
1N8  A 501 ( 3.3A)
1N8  A 501 ( 3.7A)
1N8  A 501 ( 3.5A)
1N8  A 501 ( 4.3A)
 0.76A 3k54A-2og8A:
31.4		 3k54A-2og8A:
39.72
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3K5V_A_STIA2_1
(TYROSINE-PROTEIN
KINASE ABL1)		 2og8 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE LCK
(Homo
sapiens) 		9 / 12 VAL A 259
ALA A 271
GLU A 288
MET A 292
THR A 316
GLY A 322
LEU A 371
ALA A 381
ASP A 382
 None
1N8  A 501 ( 3.4A)
1N8  A 501 ( 3.6A)
1N8  A 501 ( 3.6A)
1N8  A 501 ( 3.3A)
1N8  A 501 ( 3.5A)
1N8  A 501 ( 4.3A)
1N8  A 501 ( 3.3A)
1N8  A 501 ( 3.3A)
 0.56A 3k5vA-2og8A:
31.6		 3k5vA-2og8A:
45.30
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3K5V_A_STIA2_2
(TYROSINE-PROTEIN
KINASE ABL1)		 2og8 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE LCK
(Homo
sapiens) 		4 / 6 LEU A 251
VAL A 301
ILE A 314
MET A 319
 None
None
1N8  A 501 ( 4.6A)
1N8  A 501 ( 4.4A)
 0.60A 3k5vA-2og8A:
31.6		 3k5vA-2og8A:
45.30
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3K5V_B_STIB2_1
(TYROSINE-PROTEIN
KINASE ABL1)		 2og8 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE LCK
(Homo
sapiens) 		9 / 12 VAL A 259
ALA A 271
GLU A 288
MET A 292
THR A 316
GLY A 322
LEU A 371
ALA A 381
ASP A 382
 None
1N8  A 501 ( 3.4A)
1N8  A 501 ( 3.6A)
1N8  A 501 ( 3.6A)
1N8  A 501 ( 3.3A)
1N8  A 501 ( 3.5A)
1N8  A 501 ( 4.3A)
1N8  A 501 ( 3.3A)
1N8  A 501 ( 3.3A)
 0.56A 3k5vB-2og8A:
26.4		 3k5vB-2og8A:
45.30
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3K5V_B_STIB2_2
(TYROSINE-PROTEIN
KINASE ABL1)		 2og8 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE LCK
(Homo
sapiens) 		4 / 6 LEU A 251
VAL A 301
ILE A 314
MET A 319
 None
None
1N8  A 501 ( 4.6A)
1N8  A 501 ( 4.4A)
 0.67A 3k5vB-2og8A:
26.4		 3k5vB-2og8A:
45.30
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LFA_A_1N1A361_1
(MITOGEN-ACTIVATED
PROTEIN KINASE 14)		 2og8 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE LCK
(Homo
sapiens) 		5 / 8 ALA A 271
LYS A 273
GLU A 288
THR A 316
MET A 319
 1N8  A 501 ( 3.4A)
1N8  A 501 ( 3.4A)
1N8  A 501 ( 3.6A)
1N8  A 501 ( 3.3A)
1N8  A 501 ( 4.4A)
 0.56A 3lfaA-2og8A:
6.4		 3lfaA-2og8A:
26.59
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3MIY_A_B49A1_1
(TYROSINE-PROTEIN
KINASE ITK/TSK)		 2og8 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE LCK
(Homo
sapiens) 		6 / 11 ALA A 271
LYS A 273
VAL A 301
MET A 319
GLY A 322
LEU A 371
 1N8  A 501 ( 3.4A)
1N8  A 501 ( 3.4A)
None
1N8  A 501 ( 4.4A)
1N8  A 501 ( 3.5A)
1N8  A 501 ( 4.3A)
 0.75A 3miyA-2og8A:
32.2		 3miyA-2og8A:
42.11
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3MS9_A_STIA1_1
(TYROSINE-PROTEIN
KINASE ABL1)		 2og8 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE LCK
(Homo
sapiens) 		9 / 12 LEU A 251
VAL A 259
ALA A 271
GLU A 288
MET A 292
THR A 316
LEU A 371
ALA A 381
ASP A 382
 None
None
1N8  A 501 ( 3.4A)
1N8  A 501 ( 3.6A)
1N8  A 501 ( 3.6A)
1N8  A 501 ( 3.3A)
1N8  A 501 ( 4.3A)
1N8  A 501 ( 3.3A)
1N8  A 501 ( 3.3A)
 0.61A 3ms9A-2og8A:
31.8		 3ms9A-2og8A:
45.30
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3MS9_A_STIA1_2
(TYROSINE-PROTEIN
KINASE ABL1)		 2og8 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE LCK
(Homo
sapiens) 		4 / 6 VAL A 301
ILE A 314
MET A 319
ARG A 363
 None
1N8  A 501 ( 4.6A)
1N8  A 501 ( 4.4A)
None
 0.72A 3ms9A-2og8A:
31.8		 3ms9A-2og8A:
45.30
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3MS9_B_STIB1_1
(TYROSINE-PROTEIN
KINASE ABL1)		 2og8 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE LCK
(Homo
sapiens) 		10 / 12 LEU A 251
VAL A 259
ALA A 271
GLU A 288
MET A 292
THR A 316
GLY A 322
LEU A 371
ALA A 381
ASP A 382
 None
None
1N8  A 501 ( 3.4A)
1N8  A 501 ( 3.6A)
1N8  A 501 ( 3.6A)
1N8  A 501 ( 3.3A)
1N8  A 501 ( 3.5A)
1N8  A 501 ( 4.3A)
1N8  A 501 ( 3.3A)
1N8  A 501 ( 3.3A)
 0.65A 3ms9B-2og8A:
32.0		 3ms9B-2og8A:
45.30
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3MS9_B_STIB1_2
(TYROSINE-PROTEIN
KINASE ABL1)		 2og8 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE LCK
(Homo
sapiens) 		4 / 7 VAL A 301
ILE A 314
MET A 319
ARG A 363
 None
1N8  A 501 ( 4.6A)
1N8  A 501 ( 4.4A)
None
 1.10A 3ms9B-2og8A:
32.0		 3ms9B-2og8A:
45.30
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3MSS_A_STIA1_1
(TYROSINE-PROTEIN
KINASE ABL1)		 2og8 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE LCK
(Homo
sapiens) 		9 / 12 LEU A 251
VAL A 259
ALA A 271
GLU A 288
MET A 292
THR A 316
LEU A 371
ALA A 381
ASP A 382
 None
None
1N8  A 501 ( 3.4A)
1N8  A 501 ( 3.6A)
1N8  A 501 ( 3.6A)
1N8  A 501 ( 3.3A)
1N8  A 501 ( 4.3A)
1N8  A 501 ( 3.3A)
1N8  A 501 ( 3.3A)
 0.63A 3mssA-2og8A:
32.1		 3mssA-2og8A:
45.30
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3MSS_A_STIA1_2
(TYROSINE-PROTEIN
KINASE ABL1)		 2og8 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE LCK
(Homo
sapiens) 		4 / 6 VAL A 301
ILE A 314
MET A 319
ARG A 363
 None
1N8  A 501 ( 4.6A)
1N8  A 501 ( 4.4A)
None
 0.75A 3mssA-2og8A:
32.1		 3mssA-2og8A:
45.30
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3MSS_B_STIB1_1
(TYROSINE-PROTEIN
KINASE ABL1)		 2og8 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE LCK
(Homo
sapiens) 		8 / 12 LEU A 251
VAL A 259
GLU A 288
MET A 292
GLY A 322
LEU A 371
ALA A 381
ASP A 382
 None
None
1N8  A 501 ( 3.6A)
1N8  A 501 ( 3.6A)
1N8  A 501 ( 3.5A)
1N8  A 501 ( 4.3A)
1N8  A 501 ( 3.3A)
1N8  A 501 ( 3.3A)
 0.72A 3mssB-2og8A:
32.1		 3mssB-2og8A:
45.30
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3MSS_B_STIB1_1
(TYROSINE-PROTEIN
KINASE ABL1)		 2og8 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE LCK
(Homo
sapiens) 		9 / 12 VAL A 259
ALA A 271
GLU A 288
MET A 292
THR A 316
GLY A 322
LEU A 371
ALA A 381
ASP A 382
 None
1N8  A 501 ( 3.4A)
1N8  A 501 ( 3.6A)
1N8  A 501 ( 3.6A)
1N8  A 501 ( 3.3A)
1N8  A 501 ( 3.5A)
1N8  A 501 ( 4.3A)
1N8  A 501 ( 3.3A)
1N8  A 501 ( 3.3A)
 0.58A 3mssB-2og8A:
32.1		 3mssB-2og8A:
45.30
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3MSS_B_STIB1_2
(TYROSINE-PROTEIN
KINASE ABL1)		 2og8 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE LCK
(Homo
sapiens) 		4 / 7 VAL A 301
ILE A 314
MET A 319
ARG A 363
 None
1N8  A 501 ( 4.6A)
1N8  A 501 ( 4.4A)
None
 0.53A 3mssB-2og8A:
32.1		 3mssB-2og8A:
45.30
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3MSS_C_STIC1_1
(TYROSINE-PROTEIN
KINASE ABL1)		 2og8 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE LCK
(Homo
sapiens) 		9 / 12 LEU A 251
VAL A 259
ALA A 271
GLU A 288
MET A 292
THR A 316
LEU A 371
ALA A 381
ASP A 382
 None
None
1N8  A 501 ( 3.4A)
1N8  A 501 ( 3.6A)
1N8  A 501 ( 3.6A)
1N8  A 501 ( 3.3A)
1N8  A 501 ( 4.3A)
1N8  A 501 ( 3.3A)
1N8  A 501 ( 3.3A)
 0.64A 3mssC-2og8A:
32.0		 3mssC-2og8A:
45.30
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3MSS_C_STIC1_2
(TYROSINE-PROTEIN
KINASE ABL1)		 2og8 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE LCK
(Homo
sapiens) 		4 / 6 VAL A 301
ILE A 314
MET A 319
ARG A 363
 None
1N8  A 501 ( 4.6A)
1N8  A 501 ( 4.4A)
None
 0.79A 3mssC-2og8A:
32.0		 3mssC-2og8A:
45.30
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3MSS_D_STID1_1
(TYROSINE-PROTEIN
KINASE ABL1)		 2og8 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE LCK
(Homo
sapiens) 		9 / 12 LEU A 251
ALA A 271
GLU A 288
MET A 292
THR A 316
GLY A 322
LEU A 371
ALA A 381
ASP A 382
 None
1N8  A 501 ( 3.4A)
1N8  A 501 ( 3.6A)
1N8  A 501 ( 3.6A)
1N8  A 501 ( 3.3A)
1N8  A 501 ( 3.5A)
1N8  A 501 ( 4.3A)
1N8  A 501 ( 3.3A)
1N8  A 501 ( 3.3A)
 0.63A 3mssD-2og8A:
32.1		 3mssD-2og8A:
45.30
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3MSS_D_STID1_2
(TYROSINE-PROTEIN
KINASE ABL1)		 2og8 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE LCK
(Homo
sapiens) 		4 / 6 VAL A 259
VAL A 301
ILE A 314
MET A 319
 None
None
1N8  A 501 ( 4.6A)
1N8  A 501 ( 4.4A)
 0.59A 3mssD-2og8A:
32.1		 3mssD-2og8A:
45.30
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3OCT_A_1N1A663_1
(TYROSINE-PROTEIN
KINASE BTK)		 2og8 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE LCK
(Homo
sapiens) 		8 / 12 LEU A 251
ALA A 271
LYS A 273
MET A 292
THR A 316
TYR A 318
GLY A 322
LEU A 371
 None
1N8  A 501 ( 3.4A)
1N8  A 501 ( 3.4A)
1N8  A 501 ( 3.6A)
1N8  A 501 ( 3.3A)
1N8  A 501 ( 3.7A)
1N8  A 501 ( 3.5A)
1N8  A 501 ( 4.3A)
 0.68A 3octA-2og8A:
31.0		 3octA-2og8A:
42.48
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3OCT_A_1N1A663_1
(TYROSINE-PROTEIN
KINASE BTK)		 2og8 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE LCK
(Homo
sapiens) 		8 / 12 LEU A 251
ALA A 271
LYS A 273
VAL A 301
THR A 316
TYR A 318
GLY A 322
LEU A 371
 None
1N8  A 501 ( 3.4A)
1N8  A 501 ( 3.4A)
None
1N8  A 501 ( 3.3A)
1N8  A 501 ( 3.7A)
1N8  A 501 ( 3.5A)
1N8  A 501 ( 4.3A)
 0.73A 3octA-2og8A:
31.0		 3octA-2og8A:
42.48
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3OCT_A_1N1A663_1
(TYROSINE-PROTEIN
KINASE BTK)		 2og8 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE LCK
(Homo
sapiens) 		7 / 12 LEU A 251
VAL A 259
ALA A 271
LYS A 273
VAL A 301
THR A 316
TYR A 318
 None
None
1N8  A 501 ( 3.4A)
1N8  A 501 ( 3.4A)
None
1N8  A 501 ( 3.3A)
1N8  A 501 ( 3.7A)
 0.69A 3octA-2og8A:
31.0		 3octA-2og8A:
42.48
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3OCT_A_1N1A663_2
(TYROSINE-PROTEIN
KINASE BTK)		 2og8 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE LCK
(Homo
sapiens) 		4 / 5 PHE A 383
ILE A 314
MET A 319
ASN A 321
 1N8  A 501 ( 4.3A)
1N8  A 501 ( 4.6A)
1N8  A 501 ( 4.4A)
None
 0.87A 3octA-2og8A:
31.0		 3octA-2og8A:
42.48
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3OEZ_A_STIA601_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE SRC)		 2og8 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE LCK
(Homo
sapiens) 		11 / 12 VAL A 259
ALA A 271
GLU A 288
MET A 292
VAL A 301
THR A 316
TYR A 318
GLY A 322
LEU A 371
ALA A 381
ASP A 382
 None
1N8  A 501 ( 3.4A)
1N8  A 501 ( 3.6A)
1N8  A 501 ( 3.6A)
None
1N8  A 501 ( 3.3A)
1N8  A 501 ( 3.7A)
1N8  A 501 ( 3.5A)
1N8  A 501 ( 4.3A)
1N8  A 501 ( 3.3A)
1N8  A 501 ( 3.3A)
 0.51A 3oezA-2og8A:
37.0		 3oezA-2og8A:
67.17
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3OEZ_B_STIB601_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE SRC)		 2og8 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE LCK
(Homo
sapiens) 		10 / 12 VAL A 259
ALA A 271
GLU A 288
MET A 292
ILE A 314
THR A 316
TYR A 318
LEU A 371
ALA A 381
ASP A 382
 None
1N8  A 501 ( 3.4A)
1N8  A 501 ( 3.6A)
1N8  A 501 ( 3.6A)
1N8  A 501 ( 4.6A)
1N8  A 501 ( 3.3A)
1N8  A 501 ( 3.7A)
1N8  A 501 ( 4.3A)
1N8  A 501 ( 3.3A)
1N8  A 501 ( 3.3A)
 0.87A 3oezB-2og8A:
36.0		 3oezB-2og8A:
67.17
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3OEZ_B_STIB601_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE SRC)		 2og8 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE LCK
(Homo
sapiens) 		10 / 12 VAL A 259
ALA A 271
LYS A 273
GLU A 288
MET A 292
ILE A 314
TYR A 318
LEU A 371
ALA A 381
ASP A 382
 None
1N8  A 501 ( 3.4A)
1N8  A 501 ( 3.4A)
1N8  A 501 ( 3.6A)
1N8  A 501 ( 3.6A)
1N8  A 501 ( 4.6A)
1N8  A 501 ( 3.7A)
1N8  A 501 ( 4.3A)
1N8  A 501 ( 3.3A)
1N8  A 501 ( 3.3A)
 1.00A 3oezB-2og8A:
36.0		 3oezB-2og8A:
67.17
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3OXZ_A_0LIA1_1
(TYROSINE-PROTEIN
KINASE ABL1)		 2og8 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE LCK
(Homo
sapiens) 		11 / 12 ALA A 271
GLU A 288
MET A 292
LEU A 300
VAL A 301
THR A 316
GLY A 322
HIS A 362
ALA A 381
ASP A 382
PHE A 383
 1N8  A 501 ( 3.4A)
1N8  A 501 ( 3.6A)
1N8  A 501 ( 3.6A)
1N8  A 501 ( 3.9A)
None
1N8  A 501 ( 3.3A)
1N8  A 501 ( 3.5A)
None
1N8  A 501 ( 3.3A)
1N8  A 501 ( 3.3A)
1N8  A 501 ( 4.3A)
 0.55A 3oxzA-2og8A:
32.1		 3oxzA-2og8A:
45.94
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3OXZ_A_0LIA1_2
(TYROSINE-PROTEIN
KINASE ABL1)		 2og8 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE LCK
(Homo
sapiens) 		5 / 9 LEU A 251
ILE A 314
MET A 319
ARG A 363
LEU A 371
 None
1N8  A 501 ( 4.6A)
1N8  A 501 ( 4.4A)
None
1N8  A 501 ( 4.3A)
 0.82A 3oxzA-2og8A:
32.1		 3oxzA-2og8A:
45.94
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3OXZ_A_0LIA1_2
(TYROSINE-PROTEIN
KINASE ABL1)		 2og8 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE LCK
(Homo
sapiens) 		5 / 9 LEU A 251
LYS A 273
ILE A 314
ARG A 363
LEU A 371
 None
1N8  A 501 ( 3.4A)
1N8  A 501 ( 4.6A)
None
1N8  A 501 ( 4.3A)
 1.04A 3oxzA-2og8A:
32.1		 3oxzA-2og8A:
45.94
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3PYY_A_STIA3_1
(V-ABL ABELSON MURINE
LEUKEMIA VIRAL
ONCOGENE HOMOLOG 1
ISOFORM B VARIANT)		 2og8 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE LCK
(Homo
sapiens) 		10 / 12 LEU A 251
VAL A 259
ALA A 271
GLU A 288
MET A 292
THR A 316
GLY A 322
LEU A 371
ALA A 381
ASP A 382
 None
None
1N8  A 501 ( 3.4A)
1N8  A 501 ( 3.6A)
1N8  A 501 ( 3.6A)
1N8  A 501 ( 3.3A)
1N8  A 501 ( 3.5A)
1N8  A 501 ( 4.3A)
1N8  A 501 ( 3.3A)
1N8  A 501 ( 3.3A)
 0.58A 3pyyA-2og8A:
32.7		 3pyyA-2og8A:
45.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3PYY_B_STIB4_1
(V-ABL ABELSON MURINE
LEUKEMIA VIRAL
ONCOGENE HOMOLOG 1
ISOFORM B VARIANT)		 2og8 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE LCK
(Homo
sapiens) 		10 / 12 LEU A 251
VAL A 259
ALA A 271
GLU A 288
MET A 292
VAL A 301
THR A 316
LEU A 371
ALA A 381
ASP A 382
 None
None
1N8  A 501 ( 3.4A)
1N8  A 501 ( 3.6A)
1N8  A 501 ( 3.6A)
None
1N8  A 501 ( 3.3A)
1N8  A 501 ( 4.3A)
1N8  A 501 ( 3.3A)
1N8  A 501 ( 3.3A)
 0.70A 3pyyB-2og8A:
32.0		 3pyyB-2og8A:
45.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3QLG_A_1N1A601_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE SRC)		 2og8 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE LCK
(Homo
sapiens) 		10 / 12 LEU A 251
ALA A 271
GLU A 288
MET A 292
VAL A 301
THR A 316
TYR A 318
GLY A 322
LEU A 371
ALA A 381
 None
1N8  A 501 ( 3.4A)
1N8  A 501 ( 3.6A)
1N8  A 501 ( 3.6A)
None
1N8  A 501 ( 3.3A)
1N8  A 501 ( 3.7A)
1N8  A 501 ( 3.5A)
1N8  A 501 ( 4.3A)
1N8  A 501 ( 3.3A)
 0.84A 3qlgA-2og8A:
35.3		 3qlgA-2og8A:
67.17
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3QLG_A_1N1A601_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE SRC)		 2og8 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE LCK
(Homo
sapiens) 		9 / 12 LEU A 251
LYS A 273
GLU A 288
MET A 292
THR A 316
TYR A 318
GLY A 322
LEU A 371
ALA A 381
 None
1N8  A 501 ( 3.4A)
1N8  A 501 ( 3.6A)
1N8  A 501 ( 3.6A)
1N8  A 501 ( 3.3A)
1N8  A 501 ( 3.7A)
1N8  A 501 ( 3.5A)
1N8  A 501 ( 4.3A)
1N8  A 501 ( 3.3A)
 0.94A 3qlgA-2og8A:
35.3		 3qlgA-2og8A:
67.17
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3QLG_A_1N1A601_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE SRC)		 2og8 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE LCK
(Homo
sapiens) 		9 / 12 LEU A 251
VAL A 259
ALA A 271
GLU A 288
MET A 292
VAL A 301
THR A 316
TYR A 318
ALA A 381
 None
None
1N8  A 501 ( 3.4A)
1N8  A 501 ( 3.6A)
1N8  A 501 ( 3.6A)
None
1N8  A 501 ( 3.3A)
1N8  A 501 ( 3.7A)
1N8  A 501 ( 3.3A)
 0.57A 3qlgA-2og8A:
35.3		 3qlgA-2og8A:
67.17
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3QLG_A_1N1A601_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE SRC)		 2og8 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE LCK
(Homo
sapiens) 		8 / 12 LEU A 251
VAL A 259
LYS A 273
GLU A 288
MET A 292
THR A 316
TYR A 318
ALA A 381
 None
None
1N8  A 501 ( 3.4A)
1N8  A 501 ( 3.6A)
1N8  A 501 ( 3.6A)
1N8  A 501 ( 3.3A)
1N8  A 501 ( 3.7A)
1N8  A 501 ( 3.3A)
 0.79A 3qlgA-2og8A:
35.3		 3qlgA-2og8A:
67.17
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3QLG_B_1N1B601_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE SRC)		 2og8 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE LCK
(Homo
sapiens) 		10 / 12 LEU A 251
ALA A 271
GLU A 288
MET A 292
VAL A 301
THR A 316
TYR A 318
GLY A 322
LEU A 371
ALA A 381
 None
1N8  A 501 ( 3.4A)
1N8  A 501 ( 3.6A)
1N8  A 501 ( 3.6A)
None
1N8  A 501 ( 3.3A)
1N8  A 501 ( 3.7A)
1N8  A 501 ( 3.5A)
1N8  A 501 ( 4.3A)
1N8  A 501 ( 3.3A)
 0.82A 3qlgB-2og8A:
28.3		 3qlgB-2og8A:
67.17
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3QLG_B_1N1B601_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE SRC)		 2og8 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE LCK
(Homo
sapiens) 		9 / 12 LEU A 251
VAL A 259
ALA A 271
GLU A 288
MET A 292
VAL A 301
THR A 316
TYR A 318
ALA A 381
 None
None
1N8  A 501 ( 3.4A)
1N8  A 501 ( 3.6A)
1N8  A 501 ( 3.6A)
None
1N8  A 501 ( 3.3A)
1N8  A 501 ( 3.7A)
1N8  A 501 ( 3.3A)
 0.55A 3qlgB-2og8A:
28.3		 3qlgB-2og8A:
67.17
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RGF_A_BAXA465_2
(CYCLIN-DEPENDENT
KINASE 8)		 2og8 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE LCK
(Homo
sapiens) 		4 / 7 LEU A 371
VAL A 301
LEU A 295
ASP A 382
 1N8  A 501 ( 4.3A)
None
1N8  A 501 ( 3.9A)
1N8  A 501 ( 3.3A)
 0.62A 3rgfA-2og8A:
21.7		 3rgfA-2og8A:
26.53
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RGF_A_BAXA465_2
(CYCLIN-DEPENDENT
KINASE 8)		 2og8 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE LCK
(Homo
sapiens) 		4 / 7 LYS A 273
LEU A 295
LEU A 371
ASP A 382
 1N8  A 501 ( 3.4A)
1N8  A 501 ( 3.9A)
1N8  A 501 ( 4.3A)
1N8  A 501 ( 3.3A)
 0.96A 3rgfA-2og8A:
21.7		 3rgfA-2og8A:
26.53
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3SXR_A_1N1A1_1
(CYTOPLASMIC
TYROSINE-PROTEIN
KINASE BMX)		 2og8 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE LCK
(Homo
sapiens) 		8 / 12 ALA A 271
MET A 292
VAL A 301
ILE A 314
THR A 316
TYR A 318
GLY A 322
LEU A 371
 1N8  A 501 ( 3.4A)
1N8  A 501 ( 3.6A)
None
1N8  A 501 ( 4.6A)
1N8  A 501 ( 3.3A)
1N8  A 501 ( 3.7A)
1N8  A 501 ( 3.5A)
1N8  A 501 ( 4.3A)
 0.58A 3sxrA-2og8A:
31.0		 3sxrA-2og8A:
44.74
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3SXR_A_1N1A1_1
(CYTOPLASMIC
TYROSINE-PROTEIN
KINASE BMX)		 2og8 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE LCK
(Homo
sapiens) 		8 / 12 LEU A 251
VAL A 259
ALA A 271
MET A 292
VAL A 301
ILE A 314
THR A 316
TYR A 318
 None
None
1N8  A 501 ( 3.4A)
1N8  A 501 ( 3.6A)
None
1N8  A 501 ( 4.6A)
1N8  A 501 ( 3.3A)
1N8  A 501 ( 3.7A)
 0.52A 3sxrA-2og8A:
31.0		 3sxrA-2og8A:
44.74
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3SXR_B_1N1B2_1
(CYTOPLASMIC
TYROSINE-PROTEIN
KINASE BMX)		 2og8 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE LCK
(Homo
sapiens) 		9 / 12 LEU A 251
VAL A 259
ALA A 271
MET A 292
VAL A 301
THR A 316
TYR A 318
GLY A 322
LEU A 371
 None
None
1N8  A 501 ( 3.4A)
1N8  A 501 ( 3.6A)
None
1N8  A 501 ( 3.3A)
1N8  A 501 ( 3.7A)
1N8  A 501 ( 3.5A)
1N8  A 501 ( 4.3A)
 0.75A 3sxrB-2og8A:
30.8		 3sxrB-2og8A:
44.74
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3UE4_A_DB8A601_1
(TYROSINE-PROTEIN
KINASE ABL1)		 2og8 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE LCK
(Homo
sapiens) 		9 / 12 LEU A 251
ALA A 271
LYS A 273
GLU A 288
ILE A 314
THR A 316
MET A 319
GLY A 322
LEU A 371
 None
1N8  A 501 ( 3.4A)
1N8  A 501 ( 3.4A)
1N8  A 501 ( 3.6A)
1N8  A 501 ( 4.6A)
1N8  A 501 ( 3.3A)
1N8  A 501 ( 4.4A)
1N8  A 501 ( 3.5A)
1N8  A 501 ( 4.3A)
 0.79A 3ue4A-2og8A:
32.2		 3ue4A-2og8A:
45.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3UE4_A_DB8A601_1
(TYROSINE-PROTEIN
KINASE ABL1)		 2og8 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE LCK
(Homo
sapiens) 		8 / 12 LEU A 251
ALA A 271
VAL A 301
ILE A 314
THR A 316
MET A 319
GLY A 322
LEU A 371
 None
1N8  A 501 ( 3.4A)
None
1N8  A 501 ( 4.6A)
1N8  A 501 ( 3.3A)
1N8  A 501 ( 4.4A)
1N8  A 501 ( 3.5A)
1N8  A 501 ( 4.3A)
 0.70A 3ue4A-2og8A:
32.2		 3ue4A-2og8A:
45.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3UE4_B_DB8B601_1
(TYROSINE-PROTEIN
KINASE ABL1)		 2og8 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE LCK
(Homo
sapiens) 		9 / 12 LEU A 251
VAL A 259
ALA A 271
GLU A 288
MET A 292
ILE A 314
THR A 316
GLY A 322
LEU A 371
 None
None
1N8  A 501 ( 3.4A)
1N8  A 501 ( 3.6A)
1N8  A 501 ( 3.6A)
1N8  A 501 ( 4.6A)
1N8  A 501 ( 3.3A)
1N8  A 501 ( 3.5A)
1N8  A 501 ( 4.3A)
 0.75A 3ue4B-2og8A:
32.3		 3ue4B-2og8A:
45.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3UE4_B_DB8B601_1
(TYROSINE-PROTEIN
KINASE ABL1)		 2og8 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE LCK
(Homo
sapiens) 		9 / 12 LEU A 251
VAL A 259
ALA A 271
MET A 292
VAL A 301
ILE A 314
THR A 316
GLY A 322
LEU A 371
 None
None
1N8  A 501 ( 3.4A)
1N8  A 501 ( 3.6A)
None
1N8  A 501 ( 4.6A)
1N8  A 501 ( 3.3A)
1N8  A 501 ( 3.5A)
1N8  A 501 ( 4.3A)
 0.68A 3ue4B-2og8A:
32.3		 3ue4B-2og8A:
45.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3UG2_A_IREA1_1
(EPIDERMAL GROWTH
FACTOR RECEPTOR)		 2og8 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE LCK
(Homo
sapiens) 		7 / 12 LEU A 251
VAL A 259
ALA A 271
LYS A 273
GLY A 322
ASP A 326
LEU A 371
 None
None
1N8  A 501 ( 3.4A)
1N8  A 501 ( 3.4A)
1N8  A 501 ( 3.5A)
None
1N8  A 501 ( 4.3A)
 0.77A 3ug2A-2og8A:
29.4		 3ug2A-2og8A:
32.73
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3UG2_A_IREA1_1
(EPIDERMAL GROWTH
FACTOR RECEPTOR)		 2og8 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE LCK
(Homo
sapiens) 		7 / 12 LEU A 251
VAL A 259
ALA A 271
MET A 319
GLY A 322
ASP A 326
LEU A 371
 None
None
1N8  A 501 ( 3.4A)
1N8  A 501 ( 4.4A)
1N8  A 501 ( 3.5A)
None
1N8  A 501 ( 4.3A)
 0.66A 3ug2A-2og8A:
29.4		 3ug2A-2og8A:
32.73
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3WZE_A_BAXA1201_2
(VASCULAR ENDOTHELIAL
GROWTH FACTOR
RECEPTOR 2)		 2og8 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE LCK
(Homo
sapiens) 		4 / 8 VAL A 301
LEU A 371
ASP A 382
PHE A 383
 None
1N8  A 501 ( 4.3A)
1N8  A 501 ( 3.3A)
1N8  A 501 ( 4.3A)
 0.64A 3wzeA-2og8A:
31.2		 3wzeA-2og8A:
39.29
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3WZE_A_BAXA1201_2
(VASCULAR ENDOTHELIAL
GROWTH FACTOR
RECEPTOR 2)		 2og8 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE LCK
(Homo
sapiens) 		4 / 8 VAL A 301
LEU A 371
ILE A 380
ASP A 382
 None
1N8  A 501 ( 4.3A)
None
1N8  A 501 ( 3.3A)
 0.21A 3wzeA-2og8A:
31.2		 3wzeA-2og8A:
39.29
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3ZOS_A_0LIA1000_1
(EPITHELIAL DISCOIDIN
DOMAIN-CONTAINING
RECEPTOR 1)		 2og8 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE LCK
(Homo
sapiens) 		10 / 12 LEU A 251
ALA A 271
LYS A 273
GLU A 288
THR A 316
HIS A 362
LEU A 371
ALA A 381
ASP A 382
PHE A 383
 None
1N8  A 501 ( 3.4A)
1N8  A 501 ( 3.4A)
1N8  A 501 ( 3.6A)
1N8  A 501 ( 3.3A)
None
1N8  A 501 ( 4.3A)
1N8  A 501 ( 3.3A)
1N8  A 501 ( 3.3A)
1N8  A 501 ( 4.3A)
 0.67A 3zosA-2og8A:
31.1		 3zosA-2og8A:
37.81
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3ZOS_A_0LIA1000_1
(EPITHELIAL DISCOIDIN
DOMAIN-CONTAINING
RECEPTOR 1)		 2og8 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE LCK
(Homo
sapiens) 		10 / 12 LEU A 251
ALA A 271
LYS A 273
THR A 316
HIS A 362
ARG A 363
LEU A 371
ALA A 381
ASP A 382
PHE A 383
 None
1N8  A 501 ( 3.4A)
1N8  A 501 ( 3.4A)
1N8  A 501 ( 3.3A)
None
None
1N8  A 501 ( 4.3A)
1N8  A 501 ( 3.3A)
1N8  A 501 ( 3.3A)
1N8  A 501 ( 4.3A)
 0.85A 3zosA-2og8A:
31.1		 3zosA-2og8A:
37.81
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3ZOS_B_0LIB1000_1
(EPITHELIAL DISCOIDIN
DOMAIN-CONTAINING
RECEPTOR 1)		 2og8 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE LCK
(Homo
sapiens) 		9 / 12 ALA A 271
LYS A 273
GLU A 288
THR A 316
HIS A 362
LEU A 371
ALA A 381
ASP A 382
PHE A 383
 1N8  A 501 ( 3.4A)
1N8  A 501 ( 3.4A)
1N8  A 501 ( 3.6A)
1N8  A 501 ( 3.3A)
None
1N8  A 501 ( 4.3A)
1N8  A 501 ( 3.3A)
1N8  A 501 ( 3.3A)
1N8  A 501 ( 4.3A)
 0.49A 3zosB-2og8A:
30.9		 3zosB-2og8A:
37.81
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3ZOS_B_0LIB1000_1
(EPITHELIAL DISCOIDIN
DOMAIN-CONTAINING
RECEPTOR 1)		 2og8 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE LCK
(Homo
sapiens) 		8 / 12 ALA A 271
THR A 316
HIS A 362
ARG A 363
LEU A 371
ALA A 381
ASP A 382
PHE A 383
 1N8  A 501 ( 3.4A)
1N8  A 501 ( 3.3A)
None
None
1N8  A 501 ( 4.3A)
1N8  A 501 ( 3.3A)
1N8  A 501 ( 3.3A)
1N8  A 501 ( 4.3A)
 0.66A 3zosB-2og8A:
30.9		 3zosB-2og8A:
37.81
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3ZOS_B_0LIB1000_2
(EPITHELIAL DISCOIDIN
DOMAIN-CONTAINING
RECEPTOR 1)		 2og8 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE LCK
(Homo
sapiens) 		5 / 9 LEU A 251
MET A 292
TYR A 318
MET A 319
ILE A 380
 None
1N8  A 501 ( 3.6A)
1N8  A 501 ( 3.7A)
1N8  A 501 ( 4.4A)
None
 0.72A 3zosB-2og8A:
30.9		 3zosB-2og8A:
37.81
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4ANQ_A_VGHA9000_1
(ALK TYROSINE KINASE
RECEPTOR)		 2og8 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE LCK
(Homo
sapiens) 		7 / 9 LEU A 251
VAL A 259
ALA A 271
MET A 319
GLY A 322
LEU A 371
ALA A 381
 None
None
1N8  A 501 ( 3.4A)
1N8  A 501 ( 4.4A)
1N8  A 501 ( 3.5A)
1N8  A 501 ( 4.3A)
1N8  A 501 ( 3.3A)
 0.89A 4anqA-2og8A:
30.2		 4anqA-2og8A:
40.48
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4ANS_A_VGHA9000_1
(ALK TYROSINE KINASE
RECEPTOR)		 2og8 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE LCK
(Homo
sapiens) 		7 / 9 LEU A 251
VAL A 259
ALA A 271
MET A 319
GLY A 322
LEU A 371
ALA A 381
 None
None
1N8  A 501 ( 3.4A)
1N8  A 501 ( 4.4A)
1N8  A 501 ( 3.5A)
1N8  A 501 ( 4.3A)
1N8  A 501 ( 3.3A)
 0.88A 4ansA-2og8A:
30.1		 4ansA-2og8A:
40.48
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4BKJ_A_STIA1000_1
(EPITHELIAL DISCOIDIN
DOMAIN-CONTAINING
RECEPTOR 1)		 2og8 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE LCK
(Homo
sapiens) 		9 / 12 VAL A 259
ALA A 271
GLU A 288
MET A 292
THR A 316
TYR A 318
LEU A 371
ALA A 381
ASP A 382
 None
1N8  A 501 ( 3.4A)
1N8  A 501 ( 3.6A)
1N8  A 501 ( 3.6A)
1N8  A 501 ( 3.3A)
1N8  A 501 ( 3.7A)
1N8  A 501 ( 4.3A)
1N8  A 501 ( 3.3A)
1N8  A 501 ( 3.3A)
 0.65A 4bkjA-2og8A:
31.5		 4bkjA-2og8A:
37.81
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4BKJ_B_STIB1000_1
(EPITHELIAL DISCOIDIN
DOMAIN-CONTAINING
RECEPTOR 1)		 2og8 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE LCK
(Homo
sapiens) 		9 / 12 VAL A 259
ALA A 271
GLU A 288
MET A 292
THR A 316
LEU A 371
ALA A 381
ASP A 382
PHE A 383
 None
1N8  A 501 ( 3.4A)
1N8  A 501 ( 3.6A)
1N8  A 501 ( 3.6A)
1N8  A 501 ( 3.3A)
1N8  A 501 ( 4.3A)
1N8  A 501 ( 3.3A)
1N8  A 501 ( 3.3A)
1N8  A 501 ( 4.3A)
 0.57A 4bkjB-2og8A:
31.4		 4bkjB-2og8A:
37.81
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4BKJ_B_STIB1000_2
(EPITHELIAL DISCOIDIN
DOMAIN-CONTAINING
RECEPTOR 1)		 2og8 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE LCK
(Homo
sapiens) 		4 / 5 LEU A 295
TYR A 318
MET A 319
ARG A 363
 1N8  A 501 ( 3.9A)
1N8  A 501 ( 3.7A)
1N8  A 501 ( 4.4A)
None
 0.84A 4bkjB-2og8A:
31.4		 4bkjB-2og8A:
37.81
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4C8B_A_0LIA1000_1
(RECEPTOR-INTERACTING
SERINE/THREONINE-PRO
TEIN KINASE 2)		 2og8 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE LCK
(Homo
sapiens) 		9 / 12 ALA A 271
LYS A 273
GLU A 288
ILE A 314
THR A 316
HIS A 362
LEU A 371
ALA A 381
ASP A 382
 1N8  A 501 ( 3.4A)
1N8  A 501 ( 3.4A)
1N8  A 501 ( 3.6A)
1N8  A 501 ( 4.6A)
1N8  A 501 ( 3.3A)
None
1N8  A 501 ( 4.3A)
1N8  A 501 ( 3.3A)
1N8  A 501 ( 3.3A)
 0.55A 4c8bA-2og8A:
27.1		 4c8bA-2og8A:
26.61
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4C8B_A_0LIA1000_1
(RECEPTOR-INTERACTING
SERINE/THREONINE-PRO
TEIN KINASE 2)		 2og8 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE LCK
(Homo
sapiens) 		9 / 12 ALA A 271
LYS A 273
GLU A 288
THR A 316
HIS A 362
LEU A 371
ALA A 381
ASP A 382
PHE A 383
 1N8  A 501 ( 3.4A)
1N8  A 501 ( 3.4A)
1N8  A 501 ( 3.6A)
1N8  A 501 ( 3.3A)
None
1N8  A 501 ( 4.3A)
1N8  A 501 ( 3.3A)
1N8  A 501 ( 3.3A)
1N8  A 501 ( 4.3A)
 0.64A 4c8bA-2og8A:
27.1		 4c8bA-2og8A:
26.61
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4C8B_A_0LIA1000_2
(RECEPTOR-INTERACTING
SERINE/THREONINE-PRO
TEIN KINASE 2)		 2og8 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE LCK
(Homo
sapiens) 		4 / 5 VAL A 259
TYR A 318
MET A 319
ILE A 380
 None
1N8  A 501 ( 3.7A)
1N8  A 501 ( 4.4A)
None
 0.74A 4c8bA-2og8A:
27.1		 4c8bA-2og8A:
26.61
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4C8B_B_0LIB1000_1
(RECEPTOR-INTERACTING
SERINE/THREONINE-PRO
TEIN KINASE 2)		 2og8 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE LCK
(Homo
sapiens) 		9 / 12 ALA A 271
LYS A 273
GLU A 288
THR A 316
HIS A 362
LEU A 371
ALA A 381
ASP A 382
PHE A 383
 1N8  A 501 ( 3.4A)
1N8  A 501 ( 3.4A)
1N8  A 501 ( 3.6A)
1N8  A 501 ( 3.3A)
None
1N8  A 501 ( 4.3A)
1N8  A 501 ( 3.3A)
1N8  A 501 ( 3.3A)
1N8  A 501 ( 4.3A)
 0.65A 4c8bB-2og8A:
27.1		 4c8bB-2og8A:
26.61
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4C8B_B_0LIB1000_2
(RECEPTOR-INTERACTING
SERINE/THREONINE-PRO
TEIN KINASE 2)		 2og8 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE LCK
(Homo
sapiens) 		3 / 3 TYR A 318
MET A 319
ILE A 380
 1N8  A 501 ( 3.7A)
1N8  A 501 ( 4.4A)
None
 0.49A 4c8bB-2og8A:
27.1		 4c8bB-2og8A:
26.61
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4CKI_A_ADNA2022_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET)		 2og8 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE LCK
(Homo
sapiens) 		6 / 11 LEU A 251
ALA A 271
TYR A 318
GLY A 322
SER A 323
LEU A 371
 None
1N8  A 501 ( 3.4A)
1N8  A 501 ( 3.7A)
1N8  A 501 ( 3.5A)
None
1N8  A 501 ( 4.3A)
 0.66A 4ckiA-2og8A:
30.2		 4ckiA-2og8A:
40.85
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4CKJ_A_ADNA2014_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET)		 2og8 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE LCK
(Homo
sapiens) 		6 / 10 LEU A 251
GLY A 252
GLY A 254
VAL A 259
ALA A 271
TYR A 318
 None
None
None
None
1N8  A 501 ( 3.4A)
1N8  A 501 ( 3.7A)
 0.53A 4ckjA-2og8A:
31.0		 4ckjA-2og8A:
40.52
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4CSV_A_STIA1265_1
(SRC-ABL TYROSINE
KINASE ANCESTOR)		 2og8 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE LCK
(Homo
sapiens) 		11 / 12 VAL A 259
ALA A 271
GLU A 288
MET A 292
VAL A 301
THR A 316
TYR A 318
LEU A 371
ALA A 381
ASP A 382
PHE A 383
 None
1N8  A 501 ( 3.4A)
1N8  A 501 ( 3.6A)
1N8  A 501 ( 3.6A)
None
1N8  A 501 ( 3.3A)
1N8  A 501 ( 3.7A)
1N8  A 501 ( 4.3A)
1N8  A 501 ( 3.3A)
1N8  A 501 ( 3.3A)
1N8  A 501 ( 4.3A)
 0.53A 4csvA-2og8A:
35.3		 4csvA-2og8A:
58.52
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4HJO_A_AQ4A1001_1
(EPIDERMAL GROWTH
FACTOR RECEPTOR)		 2og8 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE LCK
(Homo
sapiens) 		7 / 12 LEU A 251
ALA A 271
LYS A 273
THR A 316
MET A 319
GLY A 322
LEU A 371
 None
1N8  A 501 ( 3.4A)
1N8  A 501 ( 3.4A)
1N8  A 501 ( 3.3A)
1N8  A 501 ( 4.4A)
1N8  A 501 ( 3.5A)
1N8  A 501 ( 4.3A)
 0.78A 4hjoA-2og8A:
29.1		 4hjoA-2og8A:
33.33
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4HJO_A_AQ4A1001_1
(EPIDERMAL GROWTH
FACTOR RECEPTOR)		 2og8 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE LCK
(Homo
sapiens) 		7 / 12 LEU A 251
VAL A 259
ALA A 271
LYS A 273
THR A 316
MET A 319
GLY A 322
 None
None
1N8  A 501 ( 3.4A)
1N8  A 501 ( 3.4A)
1N8  A 501 ( 3.3A)
1N8  A 501 ( 4.4A)
1N8  A 501 ( 3.5A)
 0.80A 4hjoA-2og8A:
29.1		 4hjoA-2og8A:
33.33
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4MXO_A_DB8A601_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE SRC)		 2og8 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE LCK
(Homo
sapiens) 		8 / 12 LEU A 251
ALA A 271
MET A 292
VAL A 301
ILE A 314
THR A 316
TYR A 318
ASP A 382
 None
1N8  A 501 ( 3.4A)
1N8  A 501 ( 3.6A)
None
1N8  A 501 ( 4.6A)
1N8  A 501 ( 3.3A)
1N8  A 501 ( 3.7A)
1N8  A 501 ( 3.3A)
 0.72A 4mxoA-2og8A:
35.5		 4mxoA-2og8A:
67.55
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4MXO_A_DB8A601_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE SRC)		 2og8 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE LCK
(Homo
sapiens) 		9 / 12 LEU A 251
VAL A 259
ALA A 271
GLU A 288
MET A 292
VAL A 301
ILE A 314
THR A 316
TYR A 318
 None
None
1N8  A 501 ( 3.4A)
1N8  A 501 ( 3.6A)
1N8  A 501 ( 3.6A)
None
1N8  A 501 ( 4.6A)
1N8  A 501 ( 3.3A)
1N8  A 501 ( 3.7A)
 0.40A 4mxoA-2og8A:
35.5		 4mxoA-2og8A:
67.55
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4MXO_A_DB8A601_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE SRC)		 2og8 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE LCK
(Homo
sapiens) 		8 / 12 LEU A 251
VAL A 259
ALA A 271
LYS A 273
GLU A 288
ILE A 314
THR A 316
TYR A 318
 None
None
1N8  A 501 ( 3.4A)
1N8  A 501 ( 3.4A)
1N8  A 501 ( 3.6A)
1N8  A 501 ( 4.6A)
1N8  A 501 ( 3.3A)
1N8  A 501 ( 3.7A)
 0.65A 4mxoA-2og8A:
35.5		 4mxoA-2og8A:
67.55
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4MXO_A_DB8A601_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE SRC)		 2og8 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE LCK
(Homo
sapiens) 		8 / 12 LEU A 251
VAL A 259
ALA A 271
LYS A 273
ILE A 314
THR A 316
TYR A 318
GLY A 322
 None
None
1N8  A 501 ( 3.4A)
1N8  A 501 ( 3.4A)
1N8  A 501 ( 4.6A)
1N8  A 501 ( 3.3A)
1N8  A 501 ( 3.7A)
1N8  A 501 ( 3.5A)
 0.78A 4mxoA-2og8A:
35.5		 4mxoA-2og8A:
67.55
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4MXO_A_DB8A601_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE SRC)		 2og8 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE LCK
(Homo
sapiens) 		9 / 12 LEU A 251
VAL A 259
ALA A 271
MET A 292
VAL A 301
ILE A 314
THR A 316
TYR A 318
GLY A 322
 None
None
1N8  A 501 ( 3.4A)
1N8  A 501 ( 3.6A)
None
1N8  A 501 ( 4.6A)
1N8  A 501 ( 3.3A)
1N8  A 501 ( 3.7A)
1N8  A 501 ( 3.5A)
 0.77A 4mxoA-2og8A:
35.5		 4mxoA-2og8A:
67.55
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4MXO_B_DB8B601_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE SRC)		 2og8 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE LCK
(Homo
sapiens) 		8 / 12 LEU A 251
VAL A 259
ALA A 271
GLU A 288
VAL A 301
ILE A 314
THR A 316
TYR A 318
 None
None
1N8  A 501 ( 3.4A)
1N8  A 501 ( 3.6A)
None
1N8  A 501 ( 4.6A)
1N8  A 501 ( 3.3A)
1N8  A 501 ( 3.7A)
 0.47A 4mxoB-2og8A:
35.5		 4mxoB-2og8A:
67.55
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4MXO_B_DB8B601_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE SRC)		 2og8 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE LCK
(Homo
sapiens) 		8 / 12 LEU A 251
VAL A 259
ALA A 271
LYS A 273
GLU A 288
ILE A 314
THR A 316
TYR A 318
 None
None
1N8  A 501 ( 3.4A)
1N8  A 501 ( 3.4A)
1N8  A 501 ( 3.6A)
1N8  A 501 ( 4.6A)
1N8  A 501 ( 3.3A)
1N8  A 501 ( 3.7A)
 0.77A 4mxoB-2og8A:
35.5		 4mxoB-2og8A:
67.55
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4MXO_B_DB8B601_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE SRC)		 2og8 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE LCK
(Homo
sapiens) 		9 / 12 LEU A 251
VAL A 259
ALA A 271
LYS A 273
ILE A 314
THR A 316
TYR A 318
GLY A 322
LEU A 371
 None
None
1N8  A 501 ( 3.4A)
1N8  A 501 ( 3.4A)
1N8  A 501 ( 4.6A)
1N8  A 501 ( 3.3A)
1N8  A 501 ( 3.7A)
1N8  A 501 ( 3.5A)
1N8  A 501 ( 4.3A)
 0.81A 4mxoB-2og8A:
35.5		 4mxoB-2og8A:
67.55
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4MXO_B_DB8B601_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE SRC)		 2og8 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE LCK
(Homo
sapiens) 		9 / 12 LEU A 251
VAL A 259
ALA A 271
VAL A 301
ILE A 314
THR A 316
TYR A 318
GLY A 322
LEU A 371
 None
None
1N8  A 501 ( 3.4A)
None
1N8  A 501 ( 4.6A)
1N8  A 501 ( 3.3A)
1N8  A 501 ( 3.7A)
1N8  A 501 ( 3.5A)
1N8  A 501 ( 4.3A)
 0.83A 4mxoB-2og8A:
35.5		 4mxoB-2og8A:
67.55
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4MXX_A_DB8A601_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE SRC)		 2og8 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE LCK
(Homo
sapiens) 		10 / 12 LEU A 251
ALA A 271
GLU A 288
MET A 292
VAL A 301
ILE A 314
THR A 316
TYR A 318
GLY A 322
LEU A 371
 None
1N8  A 501 ( 3.4A)
1N8  A 501 ( 3.6A)
1N8  A 501 ( 3.6A)
None
1N8  A 501 ( 4.6A)
1N8  A 501 ( 3.3A)
1N8  A 501 ( 3.7A)
1N8  A 501 ( 3.5A)
1N8  A 501 ( 4.3A)
 0.88A 4mxxA-2og8A:
34.8		 4mxxA-2og8A:
67.17
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4MXX_A_DB8A601_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE SRC)		 2og8 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE LCK
(Homo
sapiens) 		9 / 12 LEU A 251
ALA A 271
LYS A 273
GLU A 288
ILE A 314
THR A 316
TYR A 318
GLY A 322
LEU A 371
 None
1N8  A 501 ( 3.4A)
1N8  A 501 ( 3.4A)
1N8  A 501 ( 3.6A)
1N8  A 501 ( 4.6A)
1N8  A 501 ( 3.3A)
1N8  A 501 ( 3.7A)
1N8  A 501 ( 3.5A)
1N8  A 501 ( 4.3A)
 0.89A 4mxxA-2og8A:
34.8		 4mxxA-2og8A:
67.17
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4MXX_B_DB8B601_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE SRC)		 2og8 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE LCK
(Homo
sapiens) 		8 / 12 LEU A 251
ALA A 271
LYS A 273
THR A 316
TYR A 318
MET A 319
GLY A 322
LEU A 371
 None
1N8  A 501 ( 3.4A)
1N8  A 501 ( 3.4A)
1N8  A 501 ( 3.3A)
1N8  A 501 ( 3.7A)
1N8  A 501 ( 4.4A)
1N8  A 501 ( 3.5A)
1N8  A 501 ( 4.3A)
 0.69A 4mxxB-2og8A:
27.8		 4mxxB-2og8A:
67.17
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4MXX_B_DB8B601_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE SRC)		 2og8 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE LCK
(Homo
sapiens) 		8 / 12 LEU A 251
ALA A 271
VAL A 301
THR A 316
TYR A 318
MET A 319
GLY A 322
LEU A 371
 None
1N8  A 501 ( 3.4A)
None
1N8  A 501 ( 3.3A)
1N8  A 501 ( 3.7A)
1N8  A 501 ( 4.4A)
1N8  A 501 ( 3.5A)
1N8  A 501 ( 4.3A)
 0.77A 4mxxB-2og8A:
27.8		 4mxxB-2og8A:
67.17
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4MXX_B_DB8B601_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE SRC)		 2og8 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE LCK
(Homo
sapiens) 		8 / 12 LEU A 251
VAL A 259
ALA A 271
LYS A 273
THR A 316
TYR A 318
MET A 319
LEU A 371
 None
None
1N8  A 501 ( 3.4A)
1N8  A 501 ( 3.4A)
1N8  A 501 ( 3.3A)
1N8  A 501 ( 3.7A)
1N8  A 501 ( 4.4A)
1N8  A 501 ( 4.3A)
 0.68A 4mxxB-2og8A:
27.8		 4mxxB-2og8A:
67.17
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4MXX_B_DB8B601_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE SRC)		 2og8 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE LCK
(Homo
sapiens) 		8 / 12 LEU A 251
VAL A 259
ALA A 271
VAL A 301
THR A 316
TYR A 318
MET A 319
LEU A 371
 None
None
1N8  A 501 ( 3.4A)
None
1N8  A 501 ( 3.3A)
1N8  A 501 ( 3.7A)
1N8  A 501 ( 4.4A)
1N8  A 501 ( 4.3A)
 0.74A 4mxxB-2og8A:
27.8		 4mxxB-2og8A:
67.17
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4MXY_B_DB8B601_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE SRC)		 2og8 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE LCK
(Homo
sapiens) 		8 / 12 LEU A 251
VAL A 259
ALA A 271
LYS A 273
TYR A 318
GLY A 322
LEU A 371
ALA A 381
 None
None
1N8  A 501 ( 3.4A)
1N8  A 501 ( 3.4A)
1N8  A 501 ( 3.7A)
1N8  A 501 ( 3.5A)
1N8  A 501 ( 4.3A)
1N8  A 501 ( 3.3A)
 0.94A 4mxyB-2og8A:
27.6		 4mxyB-2og8A:
66.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4MXY_B_DB8B601_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE SRC)		 2og8 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE LCK
(Homo
sapiens) 		8 / 12 LEU A 251
VAL A 259
ALA A 271
VAL A 301
TYR A 318
GLY A 322
LEU A 371
ALA A 381
 None
None
1N8  A 501 ( 3.4A)
None
1N8  A 501 ( 3.7A)
1N8  A 501 ( 3.5A)
1N8  A 501 ( 4.3A)
1N8  A 501 ( 3.3A)
 0.88A 4mxyB-2og8A:
27.6		 4mxyB-2og8A:
66.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4MXZ_B_DB8B601_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE SRC)		 2og8 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE LCK
(Homo
sapiens) 		8 / 12 LEU A 251
VAL A 259
ALA A 271
LYS A 273
TYR A 318
GLY A 322
LEU A 371
ALA A 381
 None
None
1N8  A 501 ( 3.4A)
1N8  A 501 ( 3.4A)
1N8  A 501 ( 3.7A)
1N8  A 501 ( 3.5A)
1N8  A 501 ( 4.3A)
1N8  A 501 ( 3.3A)
 0.94A 4mxzB-2og8A:
27.6		 4mxzB-2og8A:
66.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4MXZ_B_DB8B601_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE SRC)		 2og8 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE LCK
(Homo
sapiens) 		8 / 12 LEU A 251
VAL A 259
ALA A 271
VAL A 301
TYR A 318
GLY A 322
LEU A 371
ALA A 381
 None
None
1N8  A 501 ( 3.4A)
None
1N8  A 501 ( 3.7A)
1N8  A 501 ( 3.5A)
1N8  A 501 ( 4.3A)
1N8  A 501 ( 3.3A)
 0.88A 4mxzB-2og8A:
27.6		 4mxzB-2og8A:
66.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4OTW_A_DB8A1101_1
(RECEPTOR
TYROSINE-PROTEIN
KINASE ERBB-3)		 2og8 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE LCK
(Homo
sapiens) 		9 / 12 LEU A 251
VAL A 259
LYS A 273
VAL A 301
THR A 316
TYR A 318
GLY A 322
LEU A 371
ALA A 381
 None
None
1N8  A 501 ( 3.4A)
None
1N8  A 501 ( 3.3A)
1N8  A 501 ( 3.7A)
1N8  A 501 ( 3.5A)
1N8  A 501 ( 4.3A)
1N8  A 501 ( 3.3A)
 0.91A 4otwA-2og8A:
28.3		 4otwA-2og8A:
32.10
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QMN_A_DB8A401_1
(SERINE/THREONINE-PRO
TEIN KINASE 24)		 2og8 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE LCK
(Homo
sapiens) 		7 / 12 ALA A 271
LYS A 273
GLU A 288
ILE A 314
TYR A 318
ALA A 381
ASP A 382
 1N8  A 501 ( 3.4A)
1N8  A 501 ( 3.4A)
1N8  A 501 ( 3.6A)
1N8  A 501 ( 4.6A)
1N8  A 501 ( 3.7A)
1N8  A 501 ( 3.3A)
1N8  A 501 ( 3.3A)
 1.01A 4qmnA-2og8A:
26.0		 4qmnA-2og8A:
27.08
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QMN_A_DB8A401_1
(SERINE/THREONINE-PRO
TEIN KINASE 24)		 2og8 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE LCK
(Homo
sapiens) 		7 / 12 ALA A 271
LYS A 273
GLU A 288
ILE A 314
TYR A 318
LEU A 371
ALA A 381
 1N8  A 501 ( 3.4A)
1N8  A 501 ( 3.4A)
1N8  A 501 ( 3.6A)
1N8  A 501 ( 4.6A)
1N8  A 501 ( 3.7A)
1N8  A 501 ( 4.3A)
1N8  A 501 ( 3.3A)
 0.93A 4qmnA-2og8A:
26.0		 4qmnA-2og8A:
27.08
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QMS_A_1N1A401_1
(SERINE/THREONINE-PRO
TEIN KINASE 24)		 2og8 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE LCK
(Homo
sapiens) 		6 / 11 ALA A 271
LYS A 273
GLU A 288
ILE A 314
TYR A 318
LEU A 371
 1N8  A 501 ( 3.4A)
1N8  A 501 ( 3.4A)
1N8  A 501 ( 3.6A)
1N8  A 501 ( 4.6A)
1N8  A 501 ( 3.7A)
1N8  A 501 ( 4.3A)
 0.76A 4qmsA-2og8A:
25.8		 4qmsA-2og8A:
27.08
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4QRC_A_0LIA802_1
(FIBROBLAST GROWTH
FACTOR RECEPTOR 4)		 2og8 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE LCK
(Homo
sapiens) 		5 / 12 ALA A 271
ARG A 363
ALA A 381
ASP A 382
PHE A 383
 1N8  A 501 ( 3.4A)
None
1N8  A 501 ( 3.3A)
1N8  A 501 ( 3.3A)
1N8  A 501 ( 4.3A)
 1.16A 4qrcA-2og8A:
31.4		 4qrcA-2og8A:
39.41
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4QRC_A_0LIA802_1
(FIBROBLAST GROWTH
FACTOR RECEPTOR 4)		 2og8 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE LCK
(Homo
sapiens) 		6 / 12 ALA A 271
GLU A 288
MET A 292
ALA A 381
ASP A 382
PHE A 383
 1N8  A 501 ( 3.4A)
1N8  A 501 ( 3.6A)
1N8  A 501 ( 3.6A)
1N8  A 501 ( 3.3A)
1N8  A 501 ( 3.3A)
1N8  A 501 ( 4.3A)
 0.94A 4qrcA-2og8A:
31.4		 4qrcA-2og8A:
39.41
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4R7I_A_STIA1001_1
(MACROPHAGE
COLONY-STIMULATING
FACTOR 1 RECEPTOR)		 2og8 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE LCK
(Homo
sapiens) 		8 / 12 VAL A 259
ALA A 271
LYS A 273
GLU A 288
MET A 292
THR A 316
LEU A 371
ASP A 382
 None
1N8  A 501 ( 3.4A)
1N8  A 501 ( 3.4A)
1N8  A 501 ( 3.6A)
1N8  A 501 ( 3.6A)
1N8  A 501 ( 3.3A)
1N8  A 501 ( 4.3A)
1N8  A 501 ( 3.3A)
 0.75A 4r7iA-2og8A:
31.3		 4r7iA-2og8A:
38.02
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4R7I_A_STIA1001_1
(MACROPHAGE
COLONY-STIMULATING
FACTOR 1 RECEPTOR)		 2og8 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE LCK
(Homo
sapiens) 		8 / 12 VAL A 259
ALA A 271
LYS A 273
GLU A 288
THR A 316
LEU A 371
ASP A 382
PHE A 383
 None
1N8  A 501 ( 3.4A)
1N8  A 501 ( 3.4A)
1N8  A 501 ( 3.6A)
1N8  A 501 ( 3.3A)
1N8  A 501 ( 4.3A)
1N8  A 501 ( 3.3A)
1N8  A 501 ( 4.3A)
 0.94A 4r7iA-2og8A:
31.3		 4r7iA-2og8A:
38.02
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4R7I_A_STIA1001_2
(MACROPHAGE
COLONY-STIMULATING
FACTOR 1 RECEPTOR)		 2og8 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE LCK
(Homo
sapiens) 		4 / 5 LEU A 251
VAL A 301
TYR A 318
ARG A 363
 None
None
1N8  A 501 ( 3.7A)
None
 0.95A 4r7iA-2og8A:
31.3		 4r7iA-2og8A:
38.02
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4RZV_A_032A801_1
(SERINE/THREONINE-PRO
TEIN KINASE B-RAF)		 2og8 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE LCK
(Homo
sapiens) 		5 / 12 ALA A 271
LYS A 273
ILE A 314
THR A 316
SER A 323
 1N8  A 501 ( 3.4A)
1N8  A 501 ( 3.4A)
1N8  A 501 ( 4.6A)
1N8  A 501 ( 3.3A)
None
 0.53A 4rzvA-2og8A:
8.0		 4rzvA-2og8A:
33.57
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4TWP_A_AXIA601_1
(TYROSINE-PROTEIN
KINASE ABL1)		 2og8 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE LCK
(Homo
sapiens) 		9 / 12 LEU A 251
VAL A 259
ALA A 271
LYS A 273
MET A 319
GLY A 322
ASN A 369
LEU A 371
ALA A 381
 None
None
1N8  A 501 ( 3.4A)
1N8  A 501 ( 3.4A)
1N8  A 501 ( 4.4A)
1N8  A 501 ( 3.5A)
None
1N8  A 501 ( 4.3A)
1N8  A 501 ( 3.3A)
 0.74A 4twpA-2og8A:
31.1		 4twpA-2og8A:
47.60
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4TWP_B_AXIB601_1
(TYROSINE-PROTEIN
KINASE ABL1)		 2og8 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE LCK
(Homo
sapiens) 		8 / 12 LEU A 251
VAL A 259
ALA A 271
LYS A 273
MET A 319
GLY A 322
LEU A 371
ALA A 381
 None
None
1N8  A 501 ( 3.4A)
1N8  A 501 ( 3.4A)
1N8  A 501 ( 4.4A)
1N8  A 501 ( 3.5A)
1N8  A 501 ( 4.3A)
1N8  A 501 ( 3.3A)
 0.82A 4twpB-2og8A:
26.0		 4twpB-2og8A:
47.60
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4TWP_B_AXIB601_1
(TYROSINE-PROTEIN
KINASE ABL1)		 2og8 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE LCK
(Homo
sapiens) 		8 / 12 LEU A 251
VAL A 259
ALA A 271
MET A 319
GLY A 322
ASN A 369
LEU A 371
ALA A 381
 None
None
1N8  A 501 ( 3.4A)
1N8  A 501 ( 4.4A)
1N8  A 501 ( 3.5A)
None
1N8  A 501 ( 4.3A)
1N8  A 501 ( 3.3A)
 0.80A 4twpB-2og8A:
26.0		 4twpB-2og8A:
47.60
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4TYJ_A_0LIA801_1
(FIBROBLAST GROWTH
FACTOR RECEPTOR 4)		 2og8 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE LCK
(Homo
sapiens) 		8 / 12 ALA A 271
GLU A 288
MET A 292
HIS A 362
LEU A 371
ALA A 381
ASP A 382
PHE A 383
 1N8  A 501 ( 3.4A)
1N8  A 501 ( 3.6A)
1N8  A 501 ( 3.6A)
None
1N8  A 501 ( 4.3A)
1N8  A 501 ( 3.3A)
1N8  A 501 ( 3.3A)
1N8  A 501 ( 4.3A)
 0.56A 4tyjA-2og8A:
26.8		 4tyjA-2og8A:
40.74
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4U0I_A_0LIA1001_1
(MAST/STEM CELL
GROWTH FACTOR
RECEPTOR
KIT,MAST/STEM CELL
GROWTH FACTOR
RECEPTOR KIT)		 2og8 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE LCK
(Homo
sapiens) 		7 / 10 LEU A 251
GLU A 288
LEU A 295
VAL A 301
TYR A 318
ARG A 363
ILE A 380
 None
1N8  A 501 ( 3.6A)
1N8  A 501 ( 3.9A)
None
1N8  A 501 ( 3.7A)
None
None
 0.72A 4u0iA-2og8A:
31.4		 4u0iA-2og8A:
37.86
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4U0I_A_0LIA1001_1
(MAST/STEM CELL
GROWTH FACTOR
RECEPTOR
KIT,MAST/STEM CELL
GROWTH FACTOR
RECEPTOR KIT)		 2og8 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE LCK
(Homo
sapiens) 		7 / 10 LEU A 251
VAL A 259
GLU A 288
VAL A 301
TYR A 318
ARG A 363
ILE A 380
 None
None
1N8  A 501 ( 3.6A)
None
1N8  A 501 ( 3.7A)
None
None
 0.75A 4u0iA-2og8A:
31.4		 4u0iA-2og8A:
37.86
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4U0I_A_0LIA1001_2
(MAST/STEM CELL
GROWTH FACTOR
RECEPTOR
KIT,MAST/STEM CELL
GROWTH FACTOR
RECEPTOR KIT)		 2og8 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE LCK
(Homo
sapiens) 		8 / 12 ALA A 271
LYS A 273
THR A 316
GLY A 322
HIS A 362
LEU A 371
ASP A 382
PHE A 383
 1N8  A 501 ( 3.4A)
1N8  A 501 ( 3.4A)
1N8  A 501 ( 3.3A)
1N8  A 501 ( 3.5A)
None
1N8  A 501 ( 4.3A)
1N8  A 501 ( 3.3A)
1N8  A 501 ( 4.3A)
 0.64A 4u0iA-2og8A:
31.4		 4u0iA-2og8A:
37.86
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4U5J_B_RXTB601_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE SRC)		 2og8 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE LCK
(Homo
sapiens) 		8 / 9 LEU A 251
VAL A 259
ALA A 271
TYR A 318
MET A 319
GLY A 322
LEU A 371
ASP A 382
 None
None
1N8  A 501 ( 3.4A)
1N8  A 501 ( 3.7A)
1N8  A 501 ( 4.4A)
1N8  A 501 ( 3.5A)
1N8  A 501 ( 4.3A)
1N8  A 501 ( 3.3A)
 0.87A 4u5jB-2og8A:
34.4		 4u5jB-2og8A:
67.55
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4UXQ_A_0LIA1752_1
(FIBROBLAST GROWTH
FACTOR RECEPTOR 4)		 2og8 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE LCK
(Homo
sapiens) 		7 / 12 ALA A 271
GLU A 288
HIS A 362
LEU A 371
ALA A 381
ASP A 382
PHE A 383
 1N8  A 501 ( 3.4A)
1N8  A 501 ( 3.6A)
None
1N8  A 501 ( 4.3A)
1N8  A 501 ( 3.3A)
1N8  A 501 ( 3.3A)
1N8  A 501 ( 4.3A)
 0.66A 4uxqA-2og8A:
31.9		 4uxqA-2og8A:
40.74
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4UXQ_A_0LIA1752_1
(FIBROBLAST GROWTH
FACTOR RECEPTOR 4)		 2og8 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE LCK
(Homo
sapiens) 		7 / 12 LEU A 251
ALA A 271
GLU A 288
HIS A 362
ALA A 381
ASP A 382
PHE A 383
 None
1N8  A 501 ( 3.4A)
1N8  A 501 ( 3.6A)
None
1N8  A 501 ( 3.3A)
1N8  A 501 ( 3.3A)
1N8  A 501 ( 4.3A)
 0.73A 4uxqA-2og8A:
31.9		 4uxqA-2og8A:
40.74
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4V01_A_0LIA1776_1
(FIBROBLAST GROWTH
FACTOR RECEPTOR 1
(FMS-RELATED
TYROSINE KINASE 2,
PFEIFFER SYNDROME),
ISOFORM CRA_B)		 2og8 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE LCK
(Homo
sapiens) 		7 / 12 ALA A 271
GLU A 288
MET A 292
HIS A 362
ALA A 381
ASP A 382
PHE A 383
 1N8  A 501 ( 3.4A)
1N8  A 501 ( 3.6A)
1N8  A 501 ( 3.6A)
None
1N8  A 501 ( 3.3A)
1N8  A 501 ( 3.3A)
1N8  A 501 ( 4.3A)
 0.58A 4v01A-2og8A:
31.3		 4v01A-2og8A:
38.19
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4V01_A_0LIA1776_2
(FIBROBLAST GROWTH
FACTOR RECEPTOR 1
(FMS-RELATED
TYROSINE KINASE 2,
PFEIFFER SYNDROME),
ISOFORM CRA_B)		 2og8 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE LCK
(Homo
sapiens) 		6 / 9 LEU A 251
VAL A 259
LYS A 273
ARG A 363
LEU A 371
ILE A 380
 None
None
1N8  A 501 ( 3.4A)
None
1N8  A 501 ( 4.3A)
None
 1.47A 4v01A-2og8A:
31.3		 4v01A-2og8A:
38.19
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4V01_A_0LIA1776_2
(FIBROBLAST GROWTH
FACTOR RECEPTOR 1
(FMS-RELATED
TYROSINE KINASE 2,
PFEIFFER SYNDROME),
ISOFORM CRA_B)		 2og8 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE LCK
(Homo
sapiens) 		6 / 9 LEU A 251
VAL A 259
TYR A 318
ARG A 363
LEU A 371
ILE A 380
 None
None
1N8  A 501 ( 3.7A)
None
1N8  A 501 ( 4.3A)
None
 1.16A 4v01A-2og8A:
31.3		 4v01A-2og8A:
38.19
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4V01_B_0LIB1770_1
(FIBROBLAST GROWTH
FACTOR RECEPTOR 1
(FMS-RELATED
TYROSINE KINASE 2,
PFEIFFER SYNDROME),
ISOFORM CRA_B)		 2og8 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE LCK
(Homo
sapiens) 		7 / 12 ALA A 271
GLU A 288
MET A 292
HIS A 362
ALA A 381
ASP A 382
PHE A 383
 1N8  A 501 ( 3.4A)
1N8  A 501 ( 3.6A)
1N8  A 501 ( 3.6A)
None
1N8  A 501 ( 3.3A)
1N8  A 501 ( 3.3A)
1N8  A 501 ( 4.3A)
 0.59A 4v01B-2og8A:
31.6		 4v01B-2og8A:
38.19
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4V01_B_0LIB1770_2
(FIBROBLAST GROWTH
FACTOR RECEPTOR 1
(FMS-RELATED
TYROSINE KINASE 2,
PFEIFFER SYNDROME),
ISOFORM CRA_B)		 2og8 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE LCK
(Homo
sapiens) 		7 / 9 LEU A 251
VAL A 259
LYS A 273
TYR A 318
ARG A 363
LEU A 371
ILE A 380
 None
None
1N8  A 501 ( 3.4A)
1N8  A 501 ( 3.7A)
None
1N8  A 501 ( 4.3A)
None
 1.00A 4v01B-2og8A:
31.6		 4v01B-2og8A:
38.19
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4V04_A_0LIA1772_1
(FIBROBLAST GROWTH
FACTOR RECEPTOR 1
(FMS-RELATED
TYROSINE KINASE 2,
PFEIFFER SYNDROME),
ISOFORM CRA_B)		 2og8 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE LCK
(Homo
sapiens) 		6 / 12 VAL A 259
ALA A 271
GLU A 288
HIS A 362
ALA A 381
ASP A 382
 None
1N8  A 501 ( 3.4A)
1N8  A 501 ( 3.6A)
None
1N8  A 501 ( 3.3A)
1N8  A 501 ( 3.3A)
 0.65A 4v04A-2og8A:
30.8		 4v04A-2og8A:
38.19
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4V04_A_0LIA1772_2
(FIBROBLAST GROWTH
FACTOR RECEPTOR 1
(FMS-RELATED
TYROSINE KINASE 2,
PFEIFFER SYNDROME),
ISOFORM CRA_B)		 2og8 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE LCK
(Homo
sapiens) 		4 / 8 LYS A 273
LEU A 371
ILE A 380
PHE A 383
 1N8  A 501 ( 3.4A)
1N8  A 501 ( 4.3A)
None
1N8  A 501 ( 4.3A)
 0.88A 4v04A-2og8A:
30.8		 4v04A-2og8A:
38.19
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4V04_A_0LIA1772_2
(FIBROBLAST GROWTH
FACTOR RECEPTOR 1
(FMS-RELATED
TYROSINE KINASE 2,
PFEIFFER SYNDROME),
ISOFORM CRA_B)		 2og8 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE LCK
(Homo
sapiens) 		4 / 8 MET A 292
LEU A 371
ILE A 380
PHE A 383
 1N8  A 501 ( 3.6A)
1N8  A 501 ( 4.3A)
None
1N8  A 501 ( 4.3A)
 0.58A 4v04A-2og8A:
30.8		 4v04A-2og8A:
38.19
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4V04_B_0LIB1771_1
(FIBROBLAST GROWTH
FACTOR RECEPTOR 1
(FMS-RELATED
TYROSINE KINASE 2,
PFEIFFER SYNDROME),
ISOFORM CRA_B)		 2og8 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE LCK
(Homo
sapiens) 		7 / 10 LEU A 251
VAL A 259
LYS A 273
MET A 292
ARG A 363
LEU A 371
ILE A 380
 None
None
1N8  A 501 ( 3.4A)
1N8  A 501 ( 3.6A)
None
1N8  A 501 ( 4.3A)
None
 1.45A 4v04B-2og8A:
31.4		 4v04B-2og8A:
38.19
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4V04_B_0LIB1771_1
(FIBROBLAST GROWTH
FACTOR RECEPTOR 1
(FMS-RELATED
TYROSINE KINASE 2,
PFEIFFER SYNDROME),
ISOFORM CRA_B)		 2og8 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE LCK
(Homo
sapiens) 		7 / 10 LEU A 251
VAL A 259
MET A 292
TYR A 318
ARG A 363
LEU A 371
ILE A 380
 None
None
1N8  A 501 ( 3.6A)
1N8  A 501 ( 3.7A)
None
1N8  A 501 ( 4.3A)
None
 1.30A 4v04B-2og8A:
31.4		 4v04B-2og8A:
38.19
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4V04_B_0LIB1771_2
(FIBROBLAST GROWTH
FACTOR RECEPTOR 1
(FMS-RELATED
TYROSINE KINASE 2,
PFEIFFER SYNDROME),
ISOFORM CRA_B)		 2og8 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE LCK
(Homo
sapiens) 		6 / 12 ALA A 271
GLU A 288
HIS A 362
ALA A 381
ASP A 382
PHE A 383
 1N8  A 501 ( 3.4A)
1N8  A 501 ( 3.6A)
None
1N8  A 501 ( 3.3A)
1N8  A 501 ( 3.3A)
1N8  A 501 ( 4.3A)
 0.49A 4v04B-2og8A:
31.4		 4v04B-2og8A:
38.19
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4WA9_A_AXIA9000_1
(TYROSINE-PROTEIN
KINASE ABL1)		 2og8 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE LCK
(Homo
sapiens) 		7 / 11 ALA A 271
THR A 316
MET A 319
GLY A 322
ASN A 369
LEU A 371
ALA A 381
 1N8  A 501 ( 3.4A)
1N8  A 501 ( 3.3A)
1N8  A 501 ( 4.4A)
1N8  A 501 ( 3.5A)
None
1N8  A 501 ( 4.3A)
1N8  A 501 ( 3.3A)
 0.64A 4wa9A-2og8A:
27.8		 4wa9A-2og8A:
45.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4WA9_A_AXIA9000_1
(TYROSINE-PROTEIN
KINASE ABL1)		 2og8 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE LCK
(Homo
sapiens) 		7 / 11 LEU A 251
ALA A 271
THR A 316
MET A 319
GLY A 322
LEU A 371
ALA A 381
 None
1N8  A 501 ( 3.4A)
1N8  A 501 ( 3.3A)
1N8  A 501 ( 4.4A)
1N8  A 501 ( 3.5A)
1N8  A 501 ( 4.3A)
1N8  A 501 ( 3.3A)
 0.86A 4wa9A-2og8A:
27.8		 4wa9A-2og8A:
45.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4WA9_B_AXIB9000_1
(TYROSINE-PROTEIN
KINASE ABL1)		 2og8 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE LCK
(Homo
sapiens) 		8 / 12 VAL A 259
ALA A 271
LYS A 273
THR A 316
MET A 319
GLY A 322
LEU A 371
ALA A 381
 None
1N8  A 501 ( 3.4A)
1N8  A 501 ( 3.4A)
1N8  A 501 ( 3.3A)
1N8  A 501 ( 4.4A)
1N8  A 501 ( 3.5A)
1N8  A 501 ( 4.3A)
1N8  A 501 ( 3.3A)
 0.78A 4wa9B-2og8A:
31.4		 4wa9B-2og8A:
45.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4WA9_B_AXIB9000_1
(TYROSINE-PROTEIN
KINASE ABL1)		 2og8 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE LCK
(Homo
sapiens) 		8 / 12 VAL A 259
ALA A 271
THR A 316
MET A 319
GLY A 322
ASN A 369
LEU A 371
ALA A 381
 None
1N8  A 501 ( 3.4A)
1N8  A 501 ( 3.3A)
1N8  A 501 ( 4.4A)
1N8  A 501 ( 3.5A)
None
1N8  A 501 ( 4.3A)
1N8  A 501 ( 3.3A)
 0.70A 4wa9B-2og8A:
31.4		 4wa9B-2og8A:
45.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4WKQ_A_IREA1101_1
(EPIDERMAL GROWTH
FACTOR RECEPTOR)		 2og8 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE LCK
(Homo
sapiens) 		9 / 12 LEU A 251
ALA A 271
LYS A 273
GLU A 288
MET A 292
THR A 316
GLY A 322
ASP A 326
LEU A 371
 None
1N8  A 501 ( 3.4A)
1N8  A 501 ( 3.4A)
1N8  A 501 ( 3.6A)
1N8  A 501 ( 3.6A)
1N8  A 501 ( 3.3A)
1N8  A 501 ( 3.5A)
None
1N8  A 501 ( 4.3A)
 0.84A 4wkqA-2og8A:
29.2		 4wkqA-2og8A:
33.74
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4XEY_A_1N1A601_1
(TYROSINE-PROTEIN
KINASE ABL1)		 2og8 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE LCK
(Homo
sapiens) 		11 / 12 LEU A 251
VAL A 259
ALA A 271
LYS A 273
MET A 292
VAL A 301
ILE A 314
THR A 316
GLY A 322
LEU A 371
ALA A 381
 None
None
1N8  A 501 ( 3.4A)
1N8  A 501 ( 3.4A)
1N8  A 501 ( 3.6A)
None
1N8  A 501 ( 4.6A)
1N8  A 501 ( 3.3A)
1N8  A 501 ( 3.5A)
1N8  A 501 ( 4.3A)
1N8  A 501 ( 3.3A)
 0.87A 4xeyA-2og8A:
20.3		 4xeyA-2og8A:
33.82
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4XEY_B_1N1B601_1
(TYROSINE-PROTEIN
KINASE ABL1)		 2og8 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE LCK
(Homo
sapiens) 		9 / 12 LEU A 251
ALA A 271
LYS A 273
MET A 292
ILE A 314
THR A 316
GLY A 322
LEU A 371
ALA A 381
 None
1N8  A 501 ( 3.4A)
1N8  A 501 ( 3.4A)
1N8  A 501 ( 3.6A)
1N8  A 501 ( 4.6A)
1N8  A 501 ( 3.3A)
1N8  A 501 ( 3.5A)
1N8  A 501 ( 4.3A)
1N8  A 501 ( 3.3A)
 0.80A 4xeyB-2og8A:
31.2		 4xeyB-2og8A:
33.82
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4XEY_B_1N1B601_1
(TYROSINE-PROTEIN
KINASE ABL1)		 2og8 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE LCK
(Homo
sapiens) 		9 / 12 LEU A 251
ALA A 271
LYS A 273
VAL A 301
ILE A 314
THR A 316
GLY A 322
LEU A 371
ALA A 381
 None
1N8  A 501 ( 3.4A)
1N8  A 501 ( 3.4A)
None
1N8  A 501 ( 4.6A)
1N8  A 501 ( 3.3A)
1N8  A 501 ( 3.5A)
1N8  A 501 ( 4.3A)
1N8  A 501 ( 3.3A)
 0.85A 4xeyB-2og8A:
31.2		 4xeyB-2og8A:
33.82
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4XEY_B_1N1B601_1
(TYROSINE-PROTEIN
KINASE ABL1)		 2og8 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE LCK
(Homo
sapiens) 		8 / 12 LEU A 251
VAL A 259
ALA A 271
LYS A 273
MET A 292
ILE A 314
THR A 316
ALA A 381
 None
None
1N8  A 501 ( 3.4A)
1N8  A 501 ( 3.4A)
1N8  A 501 ( 3.6A)
1N8  A 501 ( 4.6A)
1N8  A 501 ( 3.3A)
1N8  A 501 ( 3.3A)
 0.75A 4xeyB-2og8A:
31.2		 4xeyB-2og8A:
33.82
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4XEY_B_1N1B601_1
(TYROSINE-PROTEIN
KINASE ABL1)		 2og8 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE LCK
(Homo
sapiens) 		8 / 12 LEU A 251
VAL A 259
ALA A 271
LYS A 273
VAL A 301
ILE A 314
THR A 316
ALA A 381
 None
None
1N8  A 501 ( 3.4A)
1N8  A 501 ( 3.4A)
None
1N8  A 501 ( 4.6A)
1N8  A 501 ( 3.3A)
1N8  A 501 ( 3.3A)
 0.78A 4xeyB-2og8A:
31.2		 4xeyB-2og8A:
33.82
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4XLI_A_1N1A601_1
(NON-SPECIFIC
PROTEIN-TYROSINE
KINASE)		 2og8 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE LCK
(Homo
sapiens) 		11 / 12 LEU A 251
ALA A 271
GLU A 288
MET A 292
VAL A 301
THR A 316
TYR A 318
MET A 319
GLY A 322
LEU A 371
ALA A 381
 None
1N8  A 501 ( 3.4A)
1N8  A 501 ( 3.6A)
1N8  A 501 ( 3.6A)
None
1N8  A 501 ( 3.3A)
1N8  A 501 ( 3.7A)
1N8  A 501 ( 4.4A)
1N8  A 501 ( 3.5A)
1N8  A 501 ( 4.3A)
1N8  A 501 ( 3.3A)
 0.69A 4xliA-2og8A:
32.1		 4xliA-2og8A:
49.08
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4XLI_A_1N1A601_1
(NON-SPECIFIC
PROTEIN-TYROSINE
KINASE)		 2og8 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE LCK
(Homo
sapiens) 		8 / 12 LEU A 251
ALA A 271
LYS A 273
GLU A 288
TYR A 318
GLY A 322
LEU A 371
ALA A 381
 None
1N8  A 501 ( 3.4A)
1N8  A 501 ( 3.4A)
1N8  A 501 ( 3.6A)
1N8  A 501 ( 3.7A)
1N8  A 501 ( 3.5A)
1N8  A 501 ( 4.3A)
1N8  A 501 ( 3.3A)
 0.93A 4xliA-2og8A:
32.1		 4xliA-2og8A:
49.08
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4XLI_B_1N1B600_1
(NON-SPECIFIC
PROTEIN-TYROSINE
KINASE)		 2og8 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE LCK
(Homo
sapiens) 		12 / 12 LEU A 251
ALA A 271
LYS A 273
GLU A 288
MET A 292
VAL A 301
ILE A 314
THR A 316
TYR A 318
GLY A 322
LEU A 371
ALA A 381
 None
1N8  A 501 ( 3.4A)
1N8  A 501 ( 3.4A)
1N8  A 501 ( 3.6A)
1N8  A 501 ( 3.6A)
None
1N8  A 501 ( 4.6A)
1N8  A 501 ( 3.3A)
1N8  A 501 ( 3.7A)
1N8  A 501 ( 3.5A)
1N8  A 501 ( 4.3A)
1N8  A 501 ( 3.3A)
 0.72A 4xliB-2og8A:
31.9		 4xliB-2og8A:
49.08
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
5AAA_A_VGHA9000_1
(ALK TYROSINE KINASE
RECEPTOR)		 2og8 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE LCK
(Homo
sapiens) 		6 / 9 LEU A 251
VAL A 259
ALA A 271
MET A 319
GLY A 322
LEU A 371
 None
None
1N8  A 501 ( 3.4A)
1N8  A 501 ( 4.4A)
1N8  A 501 ( 3.5A)
1N8  A 501 ( 4.3A)
 0.69A 5aaaA-2og8A:
30.4		 5aaaA-2og8A:
40.14
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
5AAB_A_VGHA9000_1
(ALK TYROSINE KINASE
RECEPTOR)		 2og8 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE LCK
(Homo
sapiens) 		7 / 10 LEU A 251
VAL A 259
ALA A 271
LYS A 273
MET A 319
GLY A 322
LEU A 371
 None
None
1N8  A 501 ( 3.4A)
1N8  A 501 ( 3.4A)
1N8  A 501 ( 4.4A)
1N8  A 501 ( 3.5A)
1N8  A 501 ( 4.3A)
 0.72A 5aabA-2og8A:
30.3		 5aabA-2og8A:
40.14
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
5BVW_A_1N1A1009_1
(EPITHELIAL DISCOIDIN
DOMAIN-CONTAINING
RECEPTOR 1)		 2og8 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE LCK
(Homo
sapiens) 		11 / 12 LEU A 251
VAL A 259
ALA A 271
LYS A 273
GLU A 288
MET A 292
THR A 316
TYR A 318
GLY A 322
LEU A 371
ALA A 381
 None
None
1N8  A 501 ( 3.4A)
1N8  A 501 ( 3.4A)
1N8  A 501 ( 3.6A)
1N8  A 501 ( 3.6A)
1N8  A 501 ( 3.3A)
1N8  A 501 ( 3.7A)
1N8  A 501 ( 3.5A)
1N8  A 501 ( 4.3A)
1N8  A 501 ( 3.3A)
 0.83A 5bvwA-2og8A:
30.9		 5bvwA-2og8A:
38.01
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
5H2U_B_1N1B501_1
(PROTEIN-TYROSINE
KINASE 6)		 2og8 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE LCK
(Homo
sapiens) 		6 / 12 LEU A 251
ALA A 271
ILE A 314
THR A 316
GLY A 322
LEU A 371
 None
1N8  A 501 ( 3.4A)
1N8  A 501 ( 4.6A)
1N8  A 501 ( 3.3A)
1N8  A 501 ( 3.5A)
1N8  A 501 ( 4.3A)
 0.80A 5h2uB-2og8A:
30.0		 5h2uB-2og8A:
45.59
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
5H2U_B_1N1B501_1
(PROTEIN-TYROSINE
KINASE 6)		 2og8 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE LCK
(Homo
sapiens) 		6 / 12 LEU A 251
VAL A 259
ALA A 271
LYS A 273
ILE A 314
THR A 316
 None
None
1N8  A 501 ( 3.4A)
1N8  A 501 ( 3.4A)
1N8  A 501 ( 4.6A)
1N8  A 501 ( 3.3A)
 0.64A 5h2uB-2og8A:
30.0		 5h2uB-2og8A:
45.59
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
5H2U_C_1N1C501_1
(PROTEIN-TYROSINE
KINASE 6)		 2og8 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE LCK
(Homo
sapiens) 		6 / 12 LEU A 251
ALA A 271
ILE A 314
THR A 316
GLY A 322
LEU A 371
 None
1N8  A 501 ( 3.4A)
1N8  A 501 ( 4.6A)
1N8  A 501 ( 3.3A)
1N8  A 501 ( 3.5A)
1N8  A 501 ( 4.3A)
 0.73A 5h2uC-2og8A:
29.9		 5h2uC-2og8A:
45.59
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5HES_A_032A401_1
(MITOGEN-ACTIVATED
PROTEIN KINASE
KINASE KINASE MLT)		 2og8 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE LCK
(Homo
sapiens) 		6 / 12 VAL A 259
ALA A 271
ILE A 314
THR A 316
TYR A 318
ASP A 326
 None
1N8  A 501 ( 3.4A)
1N8  A 501 ( 4.6A)
1N8  A 501 ( 3.3A)
1N8  A 501 ( 3.7A)
None
 0.64A 5hesA-2og8A:
25.7		 5hesA-2og8A:
27.78
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5HES_B_032B401_1
(MITOGEN-ACTIVATED
PROTEIN KINASE
KINASE KINASE MLT)		 2og8 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE LCK
(Homo
sapiens) 		7 / 12 VAL A 259
ALA A 271
LYS A 273
ILE A 314
THR A 316
TYR A 318
ASP A 326
 None
1N8  A 501 ( 3.4A)
1N8  A 501 ( 3.4A)
1N8  A 501 ( 4.6A)
1N8  A 501 ( 3.3A)
1N8  A 501 ( 3.7A)
None
 0.67A 5hesB-2og8A:
26.0		 5hesB-2og8A:
27.78
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
5HIE_A_P06A801_1
(SERINE/THREONINE-PRO
TEIN KINASE B-RAF)		 2og8 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE LCK
(Homo
sapiens) 		5 / 12 VAL A 259
ALA A 271
LYS A 273
ILE A 314
THR A 316
 None
1N8  A 501 ( 3.4A)
1N8  A 501 ( 3.4A)
1N8  A 501 ( 4.6A)
1N8  A 501 ( 3.3A)
 0.60A 5hieA-2og8A:
26.0		 5hieA-2og8A:
34.04
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
5HIE_B_P06B801_1
(SERINE/THREONINE-PRO
TEIN KINASE B-RAF)		 2og8 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE LCK
(Homo
sapiens) 		5 / 12 GLY A 384
ALA A 271
LYS A 273
ILE A 314
THR A 316
 1N8  A 501 ( 4.3A)
1N8  A 501 ( 3.4A)
1N8  A 501 ( 3.4A)
1N8  A 501 ( 4.6A)
1N8  A 501 ( 3.3A)
 0.80A 5hieB-2og8A:
26.0		 5hieB-2og8A:
34.04
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
5HIE_B_P06B801_1
(SERINE/THREONINE-PRO
TEIN KINASE B-RAF)		 2og8 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE LCK
(Homo
sapiens) 		5 / 12 VAL A 259
ALA A 271
LYS A 273
ILE A 314
THR A 316
 None
1N8  A 501 ( 3.4A)
1N8  A 501 ( 3.4A)
1N8  A 501 ( 4.6A)
1N8  A 501 ( 3.3A)
 0.62A 5hieB-2og8A:
26.0		 5hieB-2og8A:
34.04
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
5HIE_D_P06D801_1
(SERINE/THREONINE-PRO
TEIN KINASE B-RAF)		 2og8 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE LCK
(Homo
sapiens) 		5 / 12 GLY A 384
ALA A 271
LYS A 273
ILE A 314
THR A 316
 1N8  A 501 ( 4.3A)
1N8  A 501 ( 3.4A)
1N8  A 501 ( 3.4A)
1N8  A 501 ( 4.6A)
1N8  A 501 ( 3.3A)
 0.80A 5hieD-2og8A:
26.0		 5hieD-2og8A:
34.04
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
5HIE_D_P06D801_1
(SERINE/THREONINE-PRO
TEIN KINASE B-RAF)		 2og8 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE LCK
(Homo
sapiens) 		5 / 12 VAL A 259
ALA A 271
LYS A 273
ILE A 314
THR A 316
 None
1N8  A 501 ( 3.4A)
1N8  A 501 ( 3.4A)
1N8  A 501 ( 4.6A)
1N8  A 501 ( 3.3A)
 0.60A 5hieD-2og8A:
26.0		 5hieD-2og8A:
34.04
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
5I9X_A_DB8A1001_1
(EPHRIN TYPE-A
RECEPTOR 2)		 2og8 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE LCK
(Homo
sapiens) 		6 / 12 ALA A 271
ILE A 314
THR A 316
TYR A 318
GLY A 322
LEU A 371
 1N8  A 501 ( 3.4A)
1N8  A 501 ( 4.6A)
1N8  A 501 ( 3.3A)
1N8  A 501 ( 3.7A)
1N8  A 501 ( 3.5A)
1N8  A 501 ( 4.3A)
 0.59A 5i9xA-2og8A:
32.2		 5i9xA-2og8A:
40.78
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
5I9Y_A_1N1A1001_1
(EPHRIN TYPE-A
RECEPTOR 2)		 2og8 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE LCK
(Homo
sapiens) 		6 / 12 ALA A 271
LYS A 273
GLU A 288
MET A 292
THR A 316
TYR A 318
 1N8  A 501 ( 3.4A)
1N8  A 501 ( 3.4A)
1N8  A 501 ( 3.6A)
1N8  A 501 ( 3.6A)
1N8  A 501 ( 3.3A)
1N8  A 501 ( 3.7A)
 0.58A 5i9yA-2og8A:
32.1		 5i9yA-2og8A:
40.78
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
5I9Y_A_1N1A1001_1
(EPHRIN TYPE-A
RECEPTOR 2)		 2og8 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE LCK
(Homo
sapiens) 		7 / 12 ALA A 271
LYS A 273
MET A 292
THR A 316
TYR A 318
GLY A 322
LEU A 371
 1N8  A 501 ( 3.4A)
1N8  A 501 ( 3.4A)
1N8  A 501 ( 3.6A)
1N8  A 501 ( 3.3A)
1N8  A 501 ( 3.7A)
1N8  A 501 ( 3.5A)
1N8  A 501 ( 4.3A)
 0.57A 5i9yA-2og8A:
32.1		 5i9yA-2og8A:
40.78
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5MO4_A_NILA601_1
(TYROSINE-PROTEIN
KINASE ABL1)		 2og8 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE LCK
(Homo
sapiens) 		7 / 10 LEU A 251
VAL A 259
GLU A 288
ILE A 314
MET A 319
GLY A 322
PHE A 383
 None
None
1N8  A 501 ( 3.6A)
1N8  A 501 ( 4.6A)
1N8  A 501 ( 4.4A)
1N8  A 501 ( 3.5A)
1N8  A 501 ( 4.3A)
 0.72A 5mo4A-2og8A:
26.3		 5mo4A-2og8A:
27.82
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5MO4_A_NILA601_2
(TYROSINE-PROTEIN
KINASE ABL1)		 2og8 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE LCK
(Homo
sapiens) 		8 / 12 ALA A 271
MET A 292
LEU A 300
VAL A 301
HIS A 362
LEU A 371
ALA A 381
ASP A 382
 1N8  A 501 ( 3.4A)
1N8  A 501 ( 3.6A)
1N8  A 501 ( 3.9A)
None
None
1N8  A 501 ( 4.3A)
1N8  A 501 ( 3.3A)
1N8  A 501 ( 3.3A)
 0.65A 5mo4A-2og8A:
7.4		 5mo4A-2og8A:
27.82
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5N3H_A_NCAA401_0
(CAMP-DEPENDENT
PROTEIN KINASE
CATALYTIC SUBUNIT
ALPHA)		 2og8 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE LCK
(Homo
sapiens) 		6 / 10 LEU A 251
VAL A 259
ALA A 271
VAL A 301
TYR A 318
LEU A 371
 None
None
1N8  A 501 ( 3.4A)
None
1N8  A 501 ( 3.7A)
1N8  A 501 ( 4.3A)
 0.79A 5n3hA-2og8A:
21.5		 5n3hA-2og8A:
22.59
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TE0_A_XINA401_1
(AP2-ASSOCIATED
PROTEIN KINASE 1)		 2og8 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE LCK
(Homo
sapiens) 		7 / 12 GLU A 249
ALA A 271
GLU A 288
MET A 292
VAL A 301
GLY A 322
LEU A 371
 None
1N8  A 501 ( 3.4A)
1N8  A 501 ( 3.6A)
1N8  A 501 ( 3.6A)
None
1N8  A 501 ( 3.5A)
1N8  A 501 ( 4.3A)
 0.76A 5te0A-2og8A:
22.5		 5te0A-2og8A:
24.08
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5VCV_A_1N1A404_1
(MEMBRANE-ASSOCIATED
TYROSINE- AND
THREONINE-SPECIFIC
CDC2-INHIBITORY
KINASE)		 2og8 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE LCK
(Homo
sapiens) 		6 / 12 LEU A 251
ALA A 271
LYS A 273
GLU A 288
THR A 316
GLY A 322
 None
1N8  A 501 ( 3.4A)
1N8  A 501 ( 3.4A)
1N8  A 501 ( 3.6A)
1N8  A 501 ( 3.3A)
1N8  A 501 ( 3.5A)
 1.00A 5vcvA-2og8A:
22.6		 5vcvA-2og8A:
26.40
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5VCY_A_DB8A401_1
(MEMBRANE-ASSOCIATED
TYROSINE- AND
THREONINE-SPECIFIC
CDC2-INHIBITORY
KINASE)		 2og8 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE LCK
(Homo
sapiens) 		6 / 12 LEU A 251
VAL A 259
ALA A 271
GLU A 288
THR A 316
GLY A 322
 None
None
1N8  A 501 ( 3.4A)
1N8  A 501 ( 3.6A)
1N8  A 501 ( 3.3A)
1N8  A 501 ( 3.5A)
 0.77A 5vcyA-2og8A:
22.1		 5vcyA-2og8A:
26.40
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5VCY_A_DB8A401_1
(MEMBRANE-ASSOCIATED
TYROSINE- AND
THREONINE-SPECIFIC
CDC2-INHIBITORY
KINASE)		 2og8 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE LCK
(Homo
sapiens) 		6 / 12 LEU A 251
VAL A 259
ALA A 271
LYS A 273
GLU A 288
THR A 316
 None
None
1N8  A 501 ( 3.4A)
1N8  A 501 ( 3.4A)
1N8  A 501 ( 3.6A)
1N8  A 501 ( 3.3A)
 0.86A 5vcyA-2og8A:
22.1		 5vcyA-2og8A:
26.40
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5XV7_A_EMHA705_1
(SERINE-ARGININE (SR)
PROTEIN KINASE 1)		 2og8 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE LCK
(Homo
sapiens) 		5 / 12 LEU A 251
GLY A 252
VAL A 259
ALA A 271
ALA A 381
 None
None
None
1N8  A 501 ( 3.4A)
1N8  A 501 ( 3.3A)
 0.73A 5xv7A-2og8A:
20.7		 5xv7A-2og8A:
12.74
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5Y7Z_A_IREA401_0
(CYCLIN-G-ASSOCIATED
KINASE)		 2og8 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE LCK
(Homo
sapiens) 		7 / 12 LEU A 251
VAL A 259
ALA A 271
LYS A 273
GLU A 288
GLY A 322
LEU A 371
 None
None
1N8  A 501 ( 3.4A)
1N8  A 501 ( 3.4A)
1N8  A 501 ( 3.6A)
1N8  A 501 ( 3.5A)
1N8  A 501 ( 4.3A)
 0.88A 5y7zA-2og8A:
21.8		 5y7zA-2og8A:
18.02
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5Y7Z_A_IREA401_0
(CYCLIN-G-ASSOCIATED
KINASE)		 2og8 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE LCK
(Homo
sapiens) 		7 / 12 LEU A 251
VAL A 259
ALA A 271
LYS A 273
GLU A 288
GLY A 322
LEU A 371
 None
None
1N8  A 501 ( 3.4A)
1N8  A 501 ( 3.4A)
1N8  A 501 ( 3.6A)
1N8  A 501 ( 3.5A)
1N8  A 501 ( 4.3A)
 0.88A 5y7zA-2og8A:
21.8		 5y7zA-2og8A:
27.04
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5Y80_A_IREA401_0
(CYCLIN-G-ASSOCIATED
KINASE)		 2og8 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE LCK
(Homo
sapiens) 		8 / 12 LEU A 251
VAL A 259
ALA A 271
LYS A 273
GLU A 288
THR A 316
GLY A 322
LEU A 371
 None
None
1N8  A 501 ( 3.4A)
1N8  A 501 ( 3.4A)
1N8  A 501 ( 3.6A)
1N8  A 501 ( 3.3A)
1N8  A 501 ( 3.5A)
1N8  A 501 ( 4.3A)
 0.85A 5y80A-2og8A:
21.6		 5y80A-2og8A:
18.02
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5ZV2_A_LEVA801_1
(FIBROBLAST GROWTH
FACTOR RECEPTOR 1)		 2og8 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE LCK
(Homo
sapiens) 		8 / 12 LEU A 251
PHE A 383
VAL A 259
ALA A 271
GLU A 288
MET A 292
GLY A 322
ALA A 381
 None
1N8  A 501 ( 4.3A)
None
1N8  A 501 ( 3.4A)
1N8  A 501 ( 3.6A)
1N8  A 501 ( 3.6A)
1N8  A 501 ( 3.5A)
1N8  A 501 ( 3.3A)
 0.88A 5zv2A-2og8A:
30.0		 5zv2A-2og8A:
20.44
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5ZV2_A_LEVA801_1
(FIBROBLAST GROWTH
FACTOR RECEPTOR 1)		 2og8 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE LCK
(Homo
sapiens) 		8 / 12 LEU A 251
VAL A 259
ALA A 271
GLU A 288
MET A 292
TYR A 318
GLY A 322
ALA A 381
 None
None
1N8  A 501 ( 3.4A)
1N8  A 501 ( 3.6A)
1N8  A 501 ( 3.6A)
1N8  A 501 ( 3.7A)
1N8  A 501 ( 3.5A)
1N8  A 501 ( 3.3A)
 0.73A 5zv2A-2og8A:
30.0		 5zv2A-2og8A:
20.44
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5ZV2_B_LEVB801_1
(FIBROBLAST GROWTH
FACTOR RECEPTOR 1)		 2og8 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE LCK
(Homo
sapiens) 		9 / 12 LEU A 251
PHE A 383
VAL A 259
ALA A 271
LYS A 273
GLU A 288
MET A 292
GLY A 322
ALA A 381
 None
1N8  A 501 ( 4.3A)
None
1N8  A 501 ( 3.4A)
1N8  A 501 ( 3.4A)
1N8  A 501 ( 3.6A)
1N8  A 501 ( 3.6A)
1N8  A 501 ( 3.5A)
1N8  A 501 ( 3.3A)
 0.88A 5zv2B-2og8A:
30.1		 5zv2B-2og8A:
20.44
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6BSD_A_1N1A901_0
(EPITHELIAL DISCOIDIN
DOMAIN-CONTAINING
RECEPTOR 1)		 2og8 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE LCK
(Homo
sapiens) 		9 / 12 VAL A 259
ALA A 271
GLU A 288
MET A 292
THR A 316
TYR A 318
MET A 319
GLY A 322
LEU A 371
 None
1N8  A 501 ( 3.4A)
1N8  A 501 ( 3.6A)
1N8  A 501 ( 3.6A)
1N8  A 501 ( 3.3A)
1N8  A 501 ( 3.7A)
1N8  A 501 ( 4.4A)
1N8  A 501 ( 3.5A)
1N8  A 501 ( 4.3A)
 0.79A 6bsdA-2og8A:
30.3		 6bsdA-2og8A:
15.61
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6BSD_A_1N1A901_0
(EPITHELIAL DISCOIDIN
DOMAIN-CONTAINING
RECEPTOR 1)		 2og8 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE LCK
(Homo
sapiens) 		9 / 12 VAL A 259
ALA A 271
LYS A 273
GLU A 288
MET A 292
THR A 316
TYR A 318
GLY A 322
LEU A 371
 None
1N8  A 501 ( 3.4A)
1N8  A 501 ( 3.4A)
1N8  A 501 ( 3.6A)
1N8  A 501 ( 3.6A)
1N8  A 501 ( 3.3A)
1N8  A 501 ( 3.7A)
1N8  A 501 ( 3.5A)
1N8  A 501 ( 4.3A)
 0.83A 6bsdA-2og8A:
30.3		 6bsdA-2og8A:
15.61
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
6FNM_A_1N1A1001_1
(-)		 2og8 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE LCK
(Homo
sapiens) 		7 / 12 ALA A 271
LYS A 273
ILE A 314
THR A 316
MET A 319
GLY A 322
LEU A 371
 1N8  A 501 ( 3.4A)
1N8  A 501 ( 3.4A)
1N8  A 501 ( 4.6A)
1N8  A 501 ( 3.3A)
1N8  A 501 ( 4.4A)
1N8  A 501 ( 3.5A)
1N8  A 501 ( 4.3A)
 0.73A 6fnmA-2og8A:
32.1		 6fnmA-2og8A:
41.78
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
6FNM_A_1N1A1001_1
(-)		 2og8 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE LCK
(Homo
sapiens) 		7 / 12 ALA A 271
MET A 292
ILE A 314
THR A 316
MET A 319
GLY A 322
LEU A 371
 1N8  A 501 ( 3.4A)
1N8  A 501 ( 3.6A)
1N8  A 501 ( 4.6A)
1N8  A 501 ( 3.3A)
1N8  A 501 ( 4.4A)
1N8  A 501 ( 3.5A)
1N8  A 501 ( 4.3A)
 0.89A 6fnmA-2og8A:
32.1		 6fnmA-2og8A:
41.78
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
6FNM_A_1N1A1001_1
(-)		 2og8 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE LCK
(Homo
sapiens) 		7 / 12 VAL A 259
ALA A 271
LYS A 273
ILE A 314
THR A 316
MET A 319
LEU A 371
 None
1N8  A 501 ( 3.4A)
1N8  A 501 ( 3.4A)
1N8  A 501 ( 4.6A)
1N8  A 501 ( 3.3A)
1N8  A 501 ( 4.4A)
1N8  A 501 ( 4.3A)
 0.73A 6fnmA-2og8A:
32.1		 6fnmA-2og8A:
41.78
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6HD4_A_STIA604_0
(TYROSINE-PROTEIN
KINASE ABL1)		 2og8 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE LCK
(Homo
sapiens) 		10 / 12 VAL A 259
ALA A 271
GLU A 288
MET A 292
VAL A 301
ILE A 314
THR A 316
LEU A 371
ALA A 381
ASP A 382
 None
1N8  A 501 ( 3.4A)
1N8  A 501 ( 3.6A)
1N8  A 501 ( 3.6A)
None
1N8  A 501 ( 4.6A)
1N8  A 501 ( 3.3A)
1N8  A 501 ( 4.3A)
1N8  A 501 ( 3.3A)
1N8  A 501 ( 3.3A)
 0.57A 6hd4A-2og8A:
26.1		 6hd4A-2og8A:
16.50
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6HD4_A_STIA604_0
(TYROSINE-PROTEIN
KINASE ABL1)		 2og8 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE LCK
(Homo
sapiens) 		8 / 12 VAL A 259
ALA A 271
LYS A 273
GLU A 288
MET A 292
ILE A 314
ALA A 381
ASP A 382
 None
1N8  A 501 ( 3.4A)
1N8  A 501 ( 3.4A)
1N8  A 501 ( 3.6A)
1N8  A 501 ( 3.6A)
1N8  A 501 ( 4.6A)
1N8  A 501 ( 3.3A)
1N8  A 501 ( 3.3A)
 0.79A 6hd4A-2og8A:
26.1		 6hd4A-2og8A:
16.50
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6HD4_B_STIB602_0
(TYROSINE-PROTEIN
KINASE ABL1)		 2og8 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE LCK
(Homo
sapiens) 		10 / 12 VAL A 259
ALA A 271
GLU A 288
MET A 292
VAL A 301
ILE A 314
THR A 316
LEU A 371
ALA A 381
ASP A 382
 None
1N8  A 501 ( 3.4A)
1N8  A 501 ( 3.6A)
1N8  A 501 ( 3.6A)
None
1N8  A 501 ( 4.6A)
1N8  A 501 ( 3.3A)
1N8  A 501 ( 4.3A)
1N8  A 501 ( 3.3A)
1N8  A 501 ( 3.3A)
 0.60A 6hd4B-2og8A:
15.4		 6hd4B-2og8A:
16.50
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6HD6_A_STIA603_0
(TYROSINE-PROTEIN
KINASE ABL1)		 2og8 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE LCK
(Homo
sapiens) 		10 / 12 VAL A 259
ALA A 271
GLU A 288
MET A 292
VAL A 301
ILE A 314
THR A 316
LEU A 371
ALA A 381
ASP A 382
 None
1N8  A 501 ( 3.4A)
1N8  A 501 ( 3.6A)
1N8  A 501 ( 3.6A)
None
1N8  A 501 ( 4.6A)
1N8  A 501 ( 3.3A)
1N8  A 501 ( 4.3A)
1N8  A 501 ( 3.3A)
1N8  A 501 ( 3.3A)
 0.54A 6hd6A-2og8A:
31.4		 6hd6A-2og8A:
16.50
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6HD6_A_STIA603_0
(TYROSINE-PROTEIN
KINASE ABL1)		 2og8 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE LCK
(Homo
sapiens) 		7 / 12 VAL A 259
LYS A 273
GLU A 288
MET A 292
ILE A 314
ALA A 381
ASP A 382
 None
1N8  A 501 ( 3.4A)
1N8  A 501 ( 3.6A)
1N8  A 501 ( 3.6A)
1N8  A 501 ( 4.6A)
1N8  A 501 ( 3.3A)
1N8  A 501 ( 3.3A)
 0.86A 6hd6A-2og8A:
31.4		 6hd6A-2og8A:
16.50
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6HD6_B_STIB601_0
(TYROSINE-PROTEIN
KINASE ABL1)		 2og8 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE LCK
(Homo
sapiens) 		9 / 12 LEU A 251
VAL A 259
ALA A 271
GLU A 288
MET A 292
VAL A 301
THR A 316
LEU A 371
ASP A 382
 None
None
1N8  A 501 ( 3.4A)
1N8  A 501 ( 3.6A)
1N8  A 501 ( 3.6A)
None
1N8  A 501 ( 3.3A)
1N8  A 501 ( 4.3A)
1N8  A 501 ( 3.3A)
 0.63A 6hd6B-2og8A:
26.2		 6hd6B-2og8A:
16.50
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6HD6_B_STIB601_1
(TYROSINE-PROTEIN
KINASE ABL1)		 2og8 PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE LCK
(Homo
sapiens) 		5 / 7 ILE A 314
MET A 319
GLY A 322
ARG A 363
ALA A 381
 1N8  A 501 ( 4.6A)
1N8  A 501 ( 4.4A)
1N8  A 501 ( 3.5A)
None
1N8  A 501 ( 3.3A)
 0.61A 6hd6B-2og8A:
26.2		 6hd6B-2og8A:
16.50